IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of	:	Group Art Unit 1642
MARK L. TYKOCINSKI et al.	:	Examiner Alana M. Harris, Ph.D.
Serial No. 09/957,056	:	Attorney Docket No. 285332-00002-2
Filed September 20, 2001	:	
CELLS AND VACCINES COMPRISING CELLS HAVING TRANSFERRED PROTEINS	:	

DECLARATION OF MARK I. GREENE

I, Mark I. Greene, being duly sworn hereby declare as follows:

1. I have an M.D. from the University of Manitoba, Canada, awarded in 1972.

2. From 1973 - 1976, I was a Fellow of the Royal College of Physicians, Canada, in the Department of Internal Medicine. I was awarded a Ph.D. from the University of Manitoba in Immunology in 1977. From 1972 - 1973 I was an Intern at the Health Sciences Centre, Winnipeg, Canada and from 1973 - 1976 I was a Resident at the Health Sciences Centre in Winnipeg, Canada. From 1973-1975 I received a Medical Research Council Fellowship, Canada; from 1976-1978 I was the recipient of a Medical Research Council Fellowship in Boston; and from 1976-1977 I was a Research Fellow in Pathology, Harvard Medical School, Boston, Massachusetts.

3. From 1977 to the present I have held various faculty appointments as listed in Exhibit A, most recently as Vice Chair of Pathology, Division of Immunology and Experimental Pathology, with the University of Pennsylvania (Philadelphia, PA).

4. I have received the awards and honors and am a member in the honorary societies listed in Exhibit B.

5. I have served on the various committees and held editorial positions listed in Exhibit C.

6. I am an author of the publications listed in Exhibit D.

7. I am a named inventor on the patents listed in Exhibit E and I have an inventor's understanding of the patent system.

8. I am not a named inventor on the captioned application. However, I have carefully reviewed the application, the outstanding Office Action issued in this case, and participated in the response to the written description rejection.

9. Claim 23, as amended, recites "An isolated cell having a lipidated protein incorporated into the cell membrane, said lipidated protein having bound thereto a fusion protein, said fusion protein consisting of a first domain and a second domain, said second domain encoding a protein having a costimulatory, inhibitory or adhesion function."

10. The three classes of proteins recited in Claim 23, namely costimulatory, inhibitory and adhesion proteins, are extremely well-known to those familiar with the art. Each class of protein has multiple members, which differ in molecular structure but share important functional properties.

11. "Costimulatory proteins" consist of membrane or soluble proteins that bind to cognate receptors, termed costimulator receptors, on immune cells, and via this binding event, provide activating signals to said immune cells. The majority of membrane-anchored costimulatory proteins belong to either the tumor necrosis factor superfamily (TNFSF) or the B7 family, but other membrane-anchored proteins also function as costimulatory proteins. In addition, a variety of soluble cytokines can provide costimulatory signals to immune cells. The structure of these proteins, the structure of their cognate receptors and the pathways by which each of these categories of costimulatory proteins activate immune cells is well known and was described in the literature prior to the filing date of the present application. See, for example, Greenfield, E.A., Nguyen, K.A., Kuchroo, V.K., "CD28/B7 costimulation: a review". *Crit. Rev. Immunol.* 18:389-418, 1998, which describes the CD28/B7 pathway in great detail, and includes a discussion of many of the various costimulator proteins described in the present application. The tumor necrosis factor superfamily has similarly been well-described.

12. It is my well considered opinion that one skilled in the art could easily determine if a particular protein of interest was a costimulatory protein as intended in the present application. Numerous assays exist, including the T-cell proliferation assay described in the application, to assess whether a particular protein functions as a costimulator.

13. In view of the above, it is my well-considered opinion that the inventors on this application had complete possession of the claimed invention. The term "costimulatory protein" adequately describes a well known category of proteins, the meaning of which is understood in the art and unambiguous, and for which assays exist to determine membership in this category.

14. Inhibitory proteins consist of membrane or soluble proteins that bind to cognate receptors, termed inhibitory receptors, on immune or other cells, and via this binding event, provide inhibitory signals to said cells. Inhibitory proteins can function to desensitize activation receptor signaling, induce immune cell anergy and proliferative inhibition, and/or induce apoptosis/cell death.

A well-studied subset of inhibitory proteins are those that bind to cognate inhibitory receptors with ITIM motifs. Other well-studied inhibitory proteins are those of the tumor necrosis factor superfamily (TNFSF), some of which induce immune cell apoptosis. As with the costimulatory proteins, the structure of these proteins, the structure of their cognate receptors, and the pathways by which each of these categories of inhibitory proteins inhibit or down-regulate immune cells is well known and was described in the literature prior to the filing date of the present application. See, by way of example, Long, E.O., "Regulation of immune responses through inhibitory receptors", *Annu Rev. Immunol.* 17:875-904, 1999; and Bolland, S., Ravetch, J.V., "Inhibitory pathways triggered by ITIM-containing receptors", *Adv. Immunol.* 72:149-177, 1999. Both of these articles describe in detail many inhibitory proteins, their structure and mechanism of action, all of which was known prior to the filing date of the present application.

15. It is my well considered opinion that one skilled in the art could easily determine if a particular protein of interest was an inhibitory protein as intended in the present application. Numerous assays exist, including the T-cell proliferation assay described in the application, and the annexin V-binding apoptosis assay, both of which are well known in the art, to assess whether a particular protein functions as an inhibitory protein.

16. In view of the above, it is my well-considered opinion that the inventors on this application had complete possession of the claimed invention. As was true for the term "costimulatory", the term "inhibitory protein" adequately describes a well known category of proteins, the meaning of which is understood in the art and unambiguous, and for which assays exist to determine membership in this category.

17. "Proteins having an adhesion function" consist of membrane proteins on one cell that bind to cognate receptors on a second cell, and via this binding event, promote adherence between said first and second cells. There are numerous examples of such proteins, including, but not limited to, integrins and selectins. This category of proteins was also well-characterized prior to the filing date of the present application. See, e.g.,

Shimizu, Y., Rose, D.M., Ginsberg, M.H., "Integrins in the immune system". *Adv. Immunol.* 72:325-380, 1999, which discusses one of the major classes of proteins having an adhesion function, integrins. Other classes of adhesion molecules were similarly well-described.

18. It is my well considered opinion that one skilled in the art could easily determine if a particular protein of interest was an adhesion protein as intended in the present application. Numerous assays exist, including cell:cell conjugate formation assays, to determine if a particular protein functions as an adhesion protein.

19. In view of the above, it is my well-considered opinion that the inventors on this application had complete possession of the claimed invention. As was true for the terms "costimulatory" and "inhibitory", the term "adhesion protein" adequately describes a well known category of proteins, the meaning of which is understood in the art and unambiguous, and for which assays exist to determine membership in this category.

20. It also my well-considered opinion that one skilled in the art would easily be able to carry out the full scope of Claim 23, without undue experimentation. The specification clearly describes how to make the fusion protein of interest and how to transfer this protein to a cell, as well as how to determine if the fusion protein has been successfully transferred, and provides numerous examples of how this was carried out in practice.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Aug 2/2004
Date

Mark I. Greene, M.D., Ph.D.

EXHIBIT A

FACULTY, HOSPITAL AND ADMINISTRATIVE APPOINTMENTS

Faculty Appointments:

1977-1978	Instructor in Pathology, Harvard Medical School
1978-1980	Assistant Professor in Pathology, Harvard Medical School
1980-1985	Associate Professor of Pathology, Harvard Medical School
1982-1985	Associate Professor of Immunology, Department of Cancer Biology, Harvard University
1984-1986	Professor of Medicine, Head: Rheumatology/Immunology, Tufts University
1986-present	Director, Division of Immunology, Department of Pathology Professor of Pathology, University of Pennsylvania
1987-present	Associate Director for Fundamental Research, Cancer Center, University of Pennsylvania
1989-present	John Eckman Professor of Medical Sciences, Department of Pathology and Laboratory Medicine, University of Pennsylvania
1993-present	Vice Chair of Pathology, Division of Immunology and Experimental Pathology, University of Pennsylvania

Hospital and Administrative Appointments:

1980-1986	Consultant in Medicine, Dana Farber Cancer Centre, Boston
1986 to present	Hospital of the University of Pennsylvania

Licensure:

1973	Canadian License Registration (Manitoba)
1976	Massachusetts License Registration (38692)
1976	Fellow of the Royal College (FRCP)
1985	Pennsylvania (M.D.-033875-E)

EXHIBIT B

AWARDS, HONORS AND MEMBERSHIP IN HONORARY SOCIATIES

1966	Memorial Scholarship
1966	Sir Sam Steele Memorial Scholarship
1966	Actuarial Award
1966	University of Manitoba Scholastic Award
1966	Mathematic Association Prize
1973-1978	Medical Research Council Fellowship Award
1982	American Cancer Society Faculty Award
1985	American Society for Clinical Investigation
1985-1987	Focused Giving Award, Johnson & Johnson
1986	Lotte Strauss Award
1988-1993	Markey Trust Award-Receptor Biology
1988-1990	Trustee: Leukemia Society of America
1989	Councilor-American Society for Clinical Investigation
1989	John Eckman Professor of Medical Sciences
1991-1992	John Guggenheim Fellow
1991-1992	American Cancer Society Annual Scientific Award
1993-1996	Human Frontiers Award
1994	Bride's Magazine: Cancer Research Award
1994	Dean's Award
1995	Interurban Clinical Club
1996	Capcure Award
1996	American Association of Physicians (AAP)
1998	Stanley N. Cohen Biomedical Research Award
1998	Abramson Family Cancer Research Award
1999	Newton Abraham Professor-Oxford University (2002-2003)
2002	Ashmolean Society
2003	Master of Arts (Hon) Oxford University

EXHIBIT C

MAJOR COMMITTEE ASSIGNMENTS (NATIONAL AND REGIONAL)

1975	RH Institute Awards Committee, Canada
1978	British Society of Immunology
1980	American Association Immunologists
1982	American Association of Pathologists
1982-1985	Massachusetts Medical Association
1986	Chairman; Department of Physiology Chair Search Committee
1989	Chairman; Structural and Molecular Biology at the University of Pennsylvania-Review Committee
1989	Howard Hughes Advisory Committee-University of Pennsylvania
1995-1999	Howard Hughes Review Committee
1996-1999	NIH-NIDCD, Board of Scientific Counselors
2001- present	Scientific Advisor- Roswell Park Memoral Cancer Insitute
2001- present	Scientific Advisor- Breast Cancer program-MD Anderson
2000-2005	Riken Institute, Board of Scientific Advisors

Editorial Positions:

Journal of Immunology, ad hoc reviewer
Journal of Experimental Medicine Cell , ad hoc reviewer
Nature, ad hoc reviewer
Science, ad hoc reviewer
Cellular Immunology-Editorial Board- through 1998
Immunologic Research-Editorial Board- present
EMBO , ad hoc reviewer
DNA & Cell Biology-Editor in Chief, 1990-Present
Journal of Mammary Gland Biology and Neoplasia Editorial board-present Experimental and Molecular Pathology- Senior Editor, 2000-Present
Pathobiology -Editor, 1990-1998

EXHIBIT D

PUBLICATIONS

1. Fujimoto, S., Greene, M.I. and Sehon, A.H.: Immunosuppressor T cells in tumor bearing hosts. Immunological Communications, 4(3):207-217, 1975.

2. Greenberg, A.H. and Greene, M.I.: Non-adaptive rejection of small tumor inocula as a model of immune surveillance. Nature, 264(5584):356-357, 1976.

3. Fujimoto, S., Greene, M.I. and Sehon, A.: Regulation of the immune response to tumor antigens. I. Immunosuppressor T cells in tumor-bearing host. Journal of Immunololology, 116(3):791-799, 1976.

4. Fujimoto, S., Greene, M.I. and Sehon, A.: Regulation of the immune response to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts. Journal of Immunology, 116:800-806, 1976.

5. Greene, M.I., Fujimoto, S. and Sehon, A.: Regulation of the immune response to tumor antigens. III. Characterization of thymic suppressor factor(s) produced by the tumor-bearing host. Journal of Immunology, 119(2):757-764, 1977.

6. Greene, M.I., Pierres, A., Dorf, M.E. and Benacerraf, B.: The I-J subregion codes for determinants on suppressor factor(s) which limit the contact sensitivity response to picryl chloride. Journal of Experimental Medicine, 146:293-296, 1977.

7. Greene, M.I., Dorf, M.E., Pierres, M. and Benacerraf, B.: Reduction of syngeneic tumor growth by an anti-I-J alloantiserum. Proc. Natl. Acad. Sci. (USA), 74(11):5118-5121, 1977.

8. Greene, M.I., Sugimoto, M. and Benacerraf, B.: Mechanisms of regulation of cell-mediated immune responses. I. Effect of the route of immunization with TNP-coupled syngeneic cells on the induction and suppression of contact sensitivity to picryl chloride. Journal of Immunology, 120(5):1604-1611, 1978.

9. Perry, L., Benacerraf, B., McCluskey, R. and Greene, M.I.: Enhanced syngeneic tumor destruction by *in vivo* inhibition of suppressor T cells using anti-I-J alloantisera. American Journal of Pathology, 92:491-502, 1978.

10. Bach, B.A., Sherman, L., Benacerraf, B. and Greene, M.I.: Mechanisms of the regulation of cell-mediated immunity. II. Induction and suppression of delayed-type hypersensitivity to azobenzenearsonate-coupled syngeneic cells. Journal of Immunology, 121(4):1460-1468, 1978.

11. Perry, L., Benacerraf, B. and Greene, M.I.: Regulation of the immune response to tumor antigen. IV. Tumor antigen-specific suppressor factor(s) bear I-J determinants and induce suppressor T cells *in vivo*. Journal of Immunology, 121(6):2144-2147, 1978.

12. Greene, M.I. and Perry, L.: Regulation of the immune response to tumor antigen. VI. Differential specificities of suppressor T cells or their products and effector T cells. Journal of Immunology, 121(6):2363-2366, 1978.

13. Greene, M.I., Perry, L. and Benacerraf, B.: Regulation of the immune response to tumor antigen. V. Modulation of suppressor T-cell activity *in vivo*. American Journal of Pathology, 95:159-169, 1979.

14. Perry, L.L., Dorf, M.E., Benacerraf, B. and Greene, M.I.: Regulation of immune response to tumor antigen: Interference with syngeneic tumor immunity by anti-IA alloantisera. Proc. of Nat'l. Acad. of Sci. (USA), 76(2):920-924, 1979.

15. Chow, D.A., Greene, M.I. and Greenberg, A.H.: Macrophage dependent, NK-cell-independent "natural" surveillance of tumors in syngeneic mice. International Journal of Cancer, 23:788-797, 1979.

16. Bach, B.A., Greene, M.I., Benacerraf, B. and Nisonoff, A.: Mechanisms of regulation of cell-mediated immunity. IV. Azobenzenearsonate (ABA) specific suppressor factor(s) bear cross-reactive idiotypic determinants the expression of which is linked to the heavy-chain allotype linkage group of genes. Journal of Experimental Medicine, 149:1084-1098, 1979.

17. Weinberger, J.Z., Greene, M.I., Benacerraf, B. and Dorf, M.E.: Hapten-specific T-cell responses to 4-hydroxy-3-nitrophenyl acetyl. I. Genetic control of delayed-type hypersensitivity by V_H and I-A-region genes. Journal of Experimental Medicine, 149:1336-1348, 1979.

18. Finberg, R., Greene, M.I., Benacerraf, B. and Burakoff, S.J.: The cytolytic T lymphocyte response to trinitrophenyl modified syngeneic cells. I. Evidence for antigen specific helper T cells. Journal of Immunology, 123(3):1205-1209, 1979.

19. Finberg, R., Burakoff, S.J., Benacerraf, B. and Greene, M.I.: The cytolytic T lymphocyte response to trinitrophenyl modified syngeneic cells. II. Evidence for antigen-specific suppressor T cells. Journal of Immunology, 123(3):1210-1214, 1979.

20. Weinberger, J.Z., Germain, R.N. Ju, S.T., Greene, M.I. Benacerraf, B. and Dorf, M.E.: Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. II. Demonstration of idiotypic determinants on suppressor T cells. Journal of Experimental Medicine, 150:761-776, 1979.

21. Sy, M.S., Bach, B.A., Dohi, Y., Nisonoff, A., Benacerraf, B. and Greene, M.I.: Antigen and receptor stimulated regulatory mechanisms. I. Induction of suppressor T cells with anti-idiotype antibodies. Journal of Experimental Medicine, 150:1216-1228, 1979.

22. Sy, M.S., Bach, B.A., Brown, A., Nisonoff, A., Benacerraf, B. and Greene, M.I.: Antigen- and receptor-driven regulatory mechanisms. II. Induction of suppressor T cells with idiotype-coupled syngeneic spleen cells. Journal of Experimental Medicine, 150:1229-1240, 1979.

23. Greene, M.I., Sy, M.S., Kripke, M. and Benacerraf, B.: Impairment of antigen-presenting cell function by ultraviolet radiation. Proc. Natl. Acad. Sci. (USA), 76(12):6591-6595, 1979.

24. Bach, B.A., Greene, M.I., Benacerraf, B. and Nisonoff, A.: Mechanisms of regulation of cell-mediated immunity. IV. Azobenzenearsonate-specific suppressor factor(s) bear cross-reactive idiotypic determinants the expression of which is linked to heavy-chain allotype linkage group of genes. Journal of Experimental Medicine, 149:1084-1098, 1979.

25. Greene, M.I., Bach, B.A. and Benaceraf, B.: Mechanisms of regulation of cell-mediated immunity. III. The characterization of azobenenearsonate-specific-suppressor T-cell-derived-suppressor factors. Journal of Experimental Medicine, 149:1069-1083, 1979.

26. Perry, L.L., Kripke, M., Benacerraf, B., Dorf, M.E. and Greene, M.I.: Regulation of the immune response to tumor antigen. VIII. The effects of host specific anti-I-J antibodies on the immune response to tumors of different origin. Cellular Immunology, 51:349-359, 1980.

27. Perry, L.L., Dorf, M.E., Bach, B.A., Benacerraf, B. and Greene, M.I.: Mechanisms of regulation of cell-mediated immunity: Anti-I-A alloantisera interfere with induction and expression of T-cell-mediated immunity to cell-bound antigen *in vivo*. Clinical Immunology and Immunopathology, 15:279-292, 1980.

28. Sugimoto, M., Egashira, Y., Pierres, A. and Greene, M.I.: Species restriction in the ability of TNP-derivatized cells to induce delayed hypersensitivity responses. Cellular Immunology, 55:74-84, 1980.

29. Pierres, A., Bromberg, J.S., Sy, M.S., Benacerraf, B. and Greene, M.I.: Mechanisms of regulation of cell-mediated immunity. VI. Antigen density dependence of the induction of genetically restricted suppressor cells. Journal of Immunology, 124(1):343-348, 1980.

30. Perry, L.L., Kripke, M.L., Benacerraf, B. Dorf, M.E. and Greene, M.I.: Regulation of the immune response to tumor antigen. VIII. The effects of host specific anti-I-J antibodies on the immune response to tumors of different origins. Cellular Immunology, 51:349-359, 1980.

31. Greene, M.I., Sy, M.S., Nisonoff, A. and Benacerraf, B.: The genetic and cellular basis of antigen and receptor stimulated regulation. Molecular Immunology, 17:857-866, 1980.

32. Weiner, H.L., Greene, M.I. and Fields, B.N.: Delayed hypersensitivity in mice infected with reovirus. I. Identification of host and viral gene products responsible for the immune response. Journal of Immunology, 125:278-282, 1980.

33. Greene, M.I. and Weiner, H.L.: Delayed hypersensitivity in mice infected with reovirus. II. Induction of tolerance and suppressor T cells to viral specific gene products. Journal of Immunology, 125:283-287, 1980.

34. Perry, L.L. and Greene, M.I.: The relationship between tumor antigens and alloantigens: Cross-reactivity due to differential context of T cell antigen recognition. Journal of Immunology, 125(2):738-748, 1980.

35. Abbas, A.K., Perry, L.L., Bach, B.A. and Greene, M.I.: Idiotype-specific T cell immunity. I. Generation of effector and suppressor T lymphocytes reactive with myeloma idiotypic determinants. Journal of Immunology, 124(3):1160-1166, 1980.

36. Sy, M.S., Brown, A.R., Nisonoff, A., Benacerraf, B. and Greene, M.I.: Antigen- and receptor-driven regulatory mechanisms. III. Induction of delayed-type hypersensitivity to azobenzenearsonate with anti-cross-reactive idiotypic antibodies. Journal of Experimental Medicine, 151:896-909, 1980.

37. Letvin, N.L., Greene, M.I., Benacerraf, B. and Germain, R.N.: Immunologic effects of whole-body ultraviolet irradiation. Selective defect in splenic adherent cell function *in vitro*. Proc. Natl. Acad. Sci. (USA), 77(5):2881-2885, 1980.

38. Fox, I.J., Perry, L.L., Sy, M.S., Benacerraf, B. and Greene, M.I.: The influence of ultraviolet light irradiation on the immune system. Clinical Immunology and Immunopathology, 17:141-155, 1980.

39. Sy, M.S., Dietz, M.H., Germain, R.N., Benacerraf, B. and Greene, M.I.: Antigen- and receptor-driven regulatory mechanisms. V. The failure of idiotype-coupled spleen cells to induce unresponsiveness in animals lacking the appropriate V_H genes is caused by the lack of idiotype-matched targets. Journal of Experimental Medicine, 152:1226-1235, 1980.

40. Greene, M.I., Benacerraf, B. and Dorf, M.E.: The characterization of the delayed type hypersensitivity reaction to H-Y antigens. Immunogenetics, 11:267-273, 1980.

41. Letvin, N.L., Fox, I.J., Greene, M.I. and Germain, R.N.: Immunologic effects whole body ultraviolet (UV) irradiation. II. Defect in splenic adherent cell antigen presentation to primed T cells. Journal of Immunology, 125:1402-1404, 1980.

42. Dietz, M.H., Sy, M.S., Greene, M.I., Nisonoff, A., Benacerraf, B. and Germain, R.N.: Antigen and receptor driven regulatory mechanisms. VI. Demonstration of cross-reactive idiotype determinants on azobenzenearsonate specific antigen binding suppressor T cells producing soluble suppressor factor(s). Journal of Immunology, 125(6):2374-2380, 1980.

43. Letvin, N.L., Nepom, J.T., Greene, M.I. Benacerraf, B. and Germain, R.N.: Loss of Ia bearing splenic adherent cells after whole body ultraviolet irradiation. Journal of Immunology, 125:2550-2554, 1980.

44. Abbas, A.K., Burakoff, S.J., Gefter, M.L. and Greene, M.I.: T lymphocyte-mediated suppression of mylenoma function in vitro. III. Regulation of antibody production in hybrid mylenoma cells by T lymphocytes. Journal of Experimental Medicine, 152:969-978, 1980.

45. Bhan, A.K., Perry, L.L., Cantor, H., Benacerraf, B. and Greene, M.I.: Role of T cell sets in the rejection of a methylcholanthrene-induced sarcoma (S1509a) in syngeneic mice. American Journal of Pathology, 102:20-27, 1981.

46. Bromberg, J.S., Benacerraf, B. and Greene, M.I.: Mechanisms of regulation of cell-mediated immunity. VII. Suppressor T cells induced by suboptimal doses of antigen plus an I-J-specific allogeneic effect. Journal of Experimental Medicine, 153:437-449, 1981.

47. Dietz, M.H., Sy, M.S., Benacerraf, B., Nisonoff, A. and Greene, M.I.: Antigen- and receptor-driven regulatory mechanisms. VII. H-2-restricted anti-idiotypic suppressor factor from efferent suppressor T cells. Journal of Experimental Medicine, 153:450-463, 1981.

48. Picus, J., Germain, R.N., Fox, I.J., Greene, M.I., Benacerraf, B. and Letvin, N.L.: Immunologic effect of whole body ultraviolet (UV) irradiation. III. Defective splenic adherent cell function in Concanavalin A and alloantigen stimulated T-cell proliferation. Cellular Immunology, 63:300-307, 1981.

49. Sy, M.S., Nisonoff, A., Germain, R.N., Benacerraf, B. and Greene, M.I.: Antigen- and receptor-driven regulatory mechanisms. VIII. Suppression of idiotype-negative, *p*-Azobenzenearsonate-specific T cells results from interaction on an anti-idiotypic second-order T suppressor cell with a cross-reactive-idiotype-positive, *p*-Azobenzenearsonate-primed T cell target. Journal of Experimental Medicine, 153:1415-1425, 1981.

50. Rubin, D., Weiner, H.L., Fields, B.N. and Greene, M.I.: Immunologic tolerance following oral administration of reovirus: Requirement for two viral gene products for tolerance induction. Journal of Immunology, 127:1697-1701, 1981.

51. Perry, L.L. and Greene, M.I.: T cell subset interactions in the regulation of syngeneic tumor immunity. Federation Proceedings, 40(1):39-44, 1981.

52. Noonan, F.P., Kripke, M.L., Pedersen, G.M. and Greene, M.I.: Suppression of contact hypersensitivity in mice by ultraviolet irradiation is associated with defective antigen-presentation. Immunology, 43:527-533, 1981.

53. Schoen, R.T., Mehlman, H., Trentham, D.E., Perry, L., Greene, M.I. and David, J.R.: Autoimmunity induced by type II collagen-coupled spleen cells. Journal of Immunology, 127(6):2275-2279, 1981.

54. Fox, I.J., Sy, M.S., Benacerraf, B. and Greene, M.I.: Impairment of antigen-presenting cell function by ultraviolet radiation. II. The effect of *in vitro* ultraviolet irradiation on antigen-presenting cells. Transplantation, 31(4):262-265, 1981.

55. Greene, M.I. and Sy, M.S.: Ligand-receptor relationships in immune regulation. Federation Proceedings, 40:1458-1461, 1981.

56. Sy, M.S., Brown, A., Bach, B., Benacerraf, B., Gottlieb, P., Nisonoff, A., and Greene, M.I.: Genetic and serologic analysis of the expression of crossreactive idiotypic determinants on anti-*p*-azobenzenarsonate antibodies and *p*-azobenzenarsonate-specific suppressor T cell factors. Proc. Natl. Acad. Sci. (USA), 78(2):1143-1147, 1981.

57. Whitaker, R.B., Nepom, J.T., Sy, M.S., Takaoki, M., Gramm, C.F., Fox, I.J., Germain, R.N., Nisonoff, A., Greene, M.I. and Benacerraf, B.: Suppressor factor from a T cell hybrid inhibits delayed hypersensitivity responses to azobenzenearsonate (ABA). Proc. Natl. Acad. Sci. (USA), 78:6441-6445, 1981.

58. Hirai, Y., Dohi, Y., Sy, M., Greene, M.I. and Nisonoff, A.: Suppressor T cells induced by idiotype-coupled cells function across an allotype barrier. Journal of Immunology, 126(5):2064-2066, 1981.

59. Schoen, R.T., Greene, M.I. and Trentham, D.E.: Antigen-specific suppression of type II collagen-induced arthritis by collagen-coupled spleen cells. Journal of Immunology, 128(2):717-719, 1982.

60. Nepom, J.T., Weiner, H.L., Dichter, M., Tardieu, M., Spriggs, D., Powers, L., Fields, B. and Greene, M.I.: Identification of a hemagglutinin-specific idiotype associated with reovirus recognition shared by lymphoid and neuronal cells. Journal of Experimental Medicine, 155:155-167, 1982.

61. Bromberg, J.S., Flynn, T., Sy, M.S., Benacerraf, B. and Greene, M.I.: Antigen- and receptor-driven regulatory mechanisms. IX. T cell-T cell interaction in the generation of first-order idiotype-bearing suppressor cells. Clinical Immunology and Imunopathogy, 22:180-193, 1982.

62. Wetzig, R.P., Foster, C.S. and Greene, M.I.: Occular immune responses. I. Priming of A/J mice in the anterior chamber with azobenenearsonate-derivatized cells induces second-order-like suppressor T cells. Journal of Immunology, 128:1753-1757, 1982.

63. Greene, M.I., Perry, L.L, Kinney-Thomas, E. and Benjamin, T.L.: Specific thymus-derived (T) cell recognition of papova virus-transformed cells. Journal of Immunology, 128:732-736, 1982.

64. Greene, M.I., Ratnofsky, S., Takaoki, M., Sy, M.S., Burakoff, S., and Finberg, R.: Antigen-specific suppression of cytotoxic T cell responses: An idiotype-bearing factor regulates the cytotoxic T cell response to azobenzenearsonate-coupled cells. Journal of Immunology, 128(3):1188-1191, 1982.

65. Ginsburg, C.H., McCluskey, R., Nepom, J.T., Takaoki, M., Falchuk, A.M., Benacerraf, B. and Greene, M.I.: Antigen- and receptor-driven regulatory mechanisms. X. The induction and suppression of hapten-specific granulomas. American Journal of Pathology, 106:421-431, 1982.

66. Takaoki, M., Sy, M.S., Whitaker, B., Nepom, J., Finberg, R., Germain, R.N., Nisonoff, A., Benacerraf, B. and Greene, M.I.: Biological activity of an idiotype-bearing suppressor T cell factor produced by a long-term T cell hybridoma. Journal of Immunology, 128(1):49-53, 1982.

67. Greene, M.I., Nelles, M., Sy, M.S. and Nisonoff, A.: Regulation of immunity to the azobenzenearsonate hapten. Advances in Immunology, 32:253-300, 1982.

68. Perry, L.L. and Greene, M.I.: Antigen presentation by epidermal Langerhans cells: Loss of function following ultraviolet (UV) irradiation *in vivo*. Clinical Immunology and Immunopathology, 24:204-219, 1982.

69. Bromberg, J.S., Nepom, J.T., Benacerraf, B. and Greene, M.I.: Hapten-coupled monoclonal anti-I-A antibodies provide a first signal for the induction of suppression. Journal of Immunology, 128(2):834-837, 1982.

70. Greene, M.I., Ratnofsky, S., Takaoki, M., Sy, M.S., Burakoff, S. and Finberg, R.W.: Antigen-specific suppression of the cytoxic T cell responses: An idiotype-bearing factor regulates the cytotoxic T cell response to azobenzenearsonate-coupled cells. Journal of Immunology, 128(3):1188-1191, 1982.

71. Greene, M.I., Ginsburg, C. and Benacerraf, B.: The regulation of hapten-specific granuloma formation. Clinical Immunology and Immunopathology, 23:275-285, 1982.

72. Abbas, A.K., Takaoki, M. and Greene, M.I.: T lymphocyte-mediated suppression of myeloma function *in vitro*. IV. Generation of effector suppressor cells specific for myeloma idiotypes. Journal of Experimental Medicine, 155:1216-1221, 1982.

73. Perry, L.L. and Greene, M.I.: Conversion of immunity to suppression by in vivo administration of I-A subregion-specific antibodies. Journal of Experimental Medicine, 156:480-491, 1982.

74. Fields, B.N., and Greene, M.I.: Genetic and molecular mechanisms of viral pathogenesis: Implications for prevention and treatment. Nature, 300(4):19-23, 1982.

75. Takaoki, M. Sy, M.S., Tominaga, A., Lowy, A., Tsurufuji, M., Finberg, R., Benacerraf, B. and Greene, M.I.: I-J-Restricted interactions in the generation of azobenzenearsonate0specific suppressor T cells. Journal of Experimental Medicine, 156:1325-1334, 1982.

76. Ertl, H.C.J., Greene, M.I., Noseworthy, J.H., Fields, B.N., Nepom, J.T., Spriggs, D.R. and Finberg, R.W.: Identification of idiotypic receptors on reovirus-specific cytolytic T cells. Proc. Natl. Acad. Sci. (USA), 79:7479-7483, 1982.

77. Borel, Y., Takaoki, M., Cookson, E. and Greene, M.I.: The role of the epitope density and cross-reactivity between two different purine nucleosides coupled to cells. Clinical Immunology and Immunopathology, 26:35-46, 1983.

78. Bromberg, J.S., Delovitch, T.C., Kaufman, K. and Greene, M.I.: *In vivo* analysis of allogeneic lymphocyte interaction: Activation of suppressor T cells by an *I-J*-restricted allogeneic effect factor (AEF). Journal of Immunology, 130(5):2250-2255, 1983.

79. Drebin, J.A., Waltenbaugh, C., Schatten, S., Benacerraf, B. and Greene, M.I.: Inhibition of tumor growth by monoclonal anti-I-J antibodies. Journal of Immunology, 130(1):506-509, 1983.

80. Tominaga, A., Lefort, S., Mizel, S.B., Dambrauskas, J.T., Granstein, R., Lowky, A., Benacerraf, B. and Greene, M.I.: Molecular signals in antigen presentation I. Effects of interleukin 1 and 2 on radiation-treated antigen-presenting cells *in vivo* and *in vitro*. Clinical Immunology and Immunopathology, 29:282-293, 1983.

81. Carter, R.H., Drebin, J.A., Schatten, S., Perry, L.L. and Greene, M.I.: Regulation of the immune response to tumor antigens. IX. *In vitro* Lyt-1^+2^- cell proliferative responses to cellbound or subcellular tumor antigen. Journal of Immunology, 130(2):997-1002, 1983.

82. Tardieu, M., Noseworthy, J.H., Perry, L.L., Che, M., Greene, M.I. and Weiner, H.L.: Generation of a monoclonal antibody (Epen1) which binds selectively to murine ependymal cells. Brain Research, 277:339-346, 1983.

83. Sy, M.S., Schneeberger, E., McCluskey, R., Greene, M.I., Rosenberg, R.D. and Benacerraf, B.: Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. Cellular Immunology, 82:23-32, 1983.

84. Lowy, A., Tominaga, A., Drebin, J.A., Takaoki, M., Benacerraf, B. and Greene, M.I.: Identification of an $I\text{-}J^+$ antigen-presenting cell required for third order suppressor cell activation. Journal of Experimental Medicine, 157:353-358, 1983.

85. Noseworthy, J.H., Fields, B.N., Dichter, M.A., Sobotka, C. Pizer, E., Perry, L.L., Nepom, J.T. and Greene, M.I.: Cell receptors for the mammalian reovirus. I. Syngeneic monoclonal anti-idiotypic antibody identifies a cell surface receptor for reovirus. Journal of Immunology, 131(5):2533-2538, 1983.

86. Moser, G., Tominaga, A., Greene, M.I., Abbas, A.K.: Accessory cells in immune suppression. I. Role of I-A-positive accessory cells in effector phase suppression of myeloma function. Journal of Immunology, 131:1728, 1983.

87. Kauffman, R.S., Noseworthy, J.H., Nepom, J.T., Finberg, R., Fields, B.N. and Greene, M.I.: Cell receptors for the mammalian reovirus. II. Monoclonal anti-idiotypic antibody blocks viral binding to cells. Journal of Immunology, 131(5):2539-2541, 1983.

88. Flood, P.M., Lowy, A., Tominaga, A., Chue, B., Greene, M.I. and Gershon, R.K.: Igh Variable region-restricted T cell interactions: Genetic restriction of an antigen-specific suppressor inducer factor is imparted by an $I\text{-}J^+$ antigen-nonspecific molecule. Journal of Experimental Medicine, 158:1938-1947, 1983.

89. Ginsberg, C.H., Dambrauskas, J.T., Whitaker, R.B., Falchuk, Z.M., and Greene, M.I.: Prevention of granuloma development in the mouse using T cell hybridoma products. Journal of Immunology, 132:203-208, 1984.

90. Granstein, R.D., Tominaga, A., Mizel, S.B., Parrish, J.A., and Greene, M.I.: Molecular signals in antigen presentation. II. Activation of cytolytic cells *in vitro* after ultraviolet radiation treatment of antigen-presenting cells. Journal of Immunology, 132(5):2210-2217, 1984.

91. Carroll, A.M., Zalutsky, M., Benacerraf, B. and Greene, M.I.: Monoclonal antibodies to tissue-associated antigens as antitumor reagents. Survey and Synthesis of Pathology Research, 3:189-200, 1984.

92. Carroll, A. M., Zalutsky, M., Schatten, S., Bhan, A., Perry, L. L., Sobotka, C., Benacerraf, B., and Greene, M.I. Monoclonal Antibodies to Tissue-Specific Cell Surface Antigens. Clinical Immunology and Immunopathology, 33: 268-281, 1984.

93. Lowy, A., Flood, P.M., Tominaga, A., Drebin, J.A., Dambrauskas, J., Gershon, R.K. and Greene, M.I.: Analysis of hapten-specific T suppressor factors: Genetic restriction of TsF_1 activity analyzed with synthetic hybrid suppressor molecules. Journal of Immunology, 132(2):640-643, 1984.

94. Granstein, R.D., Lowy, A. and Greene, M.I.: Epidermal antigen-presenting cells in activation of suppression: Identification of a new functional type of ultraviolet radiation-resistent epidermal cell. Journal of Immunology, 132(2):563-565, 1984.

95. Schatten, S., Drebin, J.A., Granstein, R.D. and Greene, M.I.: Differential antigen presentation in tumor immunity. Federation Proceedings, 43(9):2460-2462, 1984.

96. Schatten, S., Drebin, J.A., Perry, L.L., Chung, W. and Greene, M.I.: Regulation of the immune response to tumor antigens. X. Activation of third-order suppressor T cells that abrogate anti-tumor immune responses. Journal of Immunology, 133(2):1064-1069, 1984.

97. Granstein, R.D., Parrish, H.A., McAuliffe, D.J., Waltenbaugh, C. and Greene, M.I.: Immunologic inhibition of ultraviolet radiation-induced tumor suppressor cell activation. Science, 224:615-617, 1984.

98. Lowy, A., Drebin, J:A., Monroe, J.G., Granstein, R.D. and Greene, M.I.: Genetically restricted antigen presentation for immunologic tolerance and suppression. Nature, 308 (22):373-374, 1984.

99. Monroe, J.G., Lowy, A., Granstein, R. and Greene, M.I.: Studies of immune responsiveness and unresponsiveness to the p-Azobenzenearsonate (ABA) hapten. Immunological Reviews, 80:103-131, 1984.

100. Sy, M.S., Lowy, A., Hayglass, K., Janeway, C.A., Gurish, M., Greene, M.I. and Benacerraf, B.: Chronic treatment with rabbit Anti-Mouse □chain antibody alters characteristic immunoglobulin heavy-chain restriction of murine suppressor T-cell factors. Proc. Natl. Acad. Sci. (USA), 81:3846-3850, 1984.

101. Schechter, A.L., Stern, D.F., Vaidyanathan, L., Decker, S.J., Drebin, J.A., Greene, M.I. and Weinberg, R.A.: The *neu* oncogene: An *erb-B*-related gene that encodes a 185,000-M_r tumor antigen. Nature, 312(6):513-516, 1984.

102. Drebin, J.A., Stern, D.F., Link, V.C., Weinberg, R.A. and Greene, M.I.: Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature, 312:545-547, 1984.

103. Sharpe, A.H., Gaulton, G.N., McDade, K.K., Fields, B.N. and Greene, M.I.: Syngeneic monoclonal anti-idiotype can induce cellular immunity to reovirus. Journal of Experimental Medicine, 160:1195-1205, 1984.

104. Sharpe, A.H., Gaulton, G.N., Ertl, G., Finberg, R.W., McDade, K.K., Fields, B.N. and Greene, M.I.: Cell receptors for the mammalian reovirus. IV. Reovirus-specific cytolytix T cell lines that have idiotypic receptors recognize anti-idiotypic B cell hybriodomas. Journal of Immunology, 134(4):2702-2706, 1985.

105. Co, M.S., Gaulton, G.N., Fields, B.N., and Greene, M.I.: Isolation and biochemical characterization of the mammalian reovirus type 3 cell-surface receptors. Proc. Natl. Acad. Sci. (USA), 82:1494-1498, 1985.

106. Co, M.S., Gaulton, G.N., Tominaga, A., Homcy, C.J., Fields, B.N. and Greene, M.I.: Structural similarities of the reovirus and □-adrenergic receptors. Proc. Natl. Acad. Sci. (USA), 82:5315-5318, 1985.

107. Gaulton, G., Co, M.S. and Greene, M.I.: Anti-idiotypic antibody identifies the cellular receptor of reovirus type 3. Journal of Cellular Biochemistry, 28:69-78, 1985.

108. Granstein, R.D. and Greene, M.I.: Splenic I-J-Bearing Antigen-Presenting Cells in Activation of Suppression: Further Characterization. Cellular Immunology, 91:12-20, 1985.

109. Monroe, J.G., Gurish, M., Dumbrauskas, J., Slaoui, M., Lowy, A. and Greene, M.I.: Genetic and Biological Characterization of a T Suppressor Cell Induced by Anti-Idiotypic Antibody. Journal of Immunology, 135(3):1589-1597, 1985.

110. Gaulton, G.N., Co, M.S., Royer, H.D. and Greene, M.I.: Anti-idiotypic antibodies as probes of cell surface receptors. Molecular and Cellular Biochemistry, 65:5-21, 1985.

111. Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A. and Greene, M.I.: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibo and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41:695-706, 1985.

112. Greene, M.I., Perry, L.L., Caroll, A. and Lowry, A.: Mechanism of regulation of immune responses by in vivo administration of monoclonal anti I-A antibodies. Immunologic Research, 4:173-178, 1985.

113. Bier, E., Hashimoto, Y., Greene, M.I. and Maxam A.: Active T-cell receptor genes have intron deoxyribonuclease hypersensitive sites. Science, 229:528-534, 1985.

114. Slaoui, M., Urbain, J., Lowy, A., Willems, F., Monroe, J.M., Benacerraf, B. and Greene, M.I.: Anti-Idiotypic treatment of BALB/c mice induces CRI_a-Bearing Suppressor Cells with altered Igh-restricted function. Journal of Immunology, 136(6):1968-1973, 1986.

115. Gaulton, G.N. and Greene, M.I.: Idiotypic mimicry of biological receptors. Annual Review of Immunology, 4:253-280, 1986.

116. Bruck, C., Co, M.S., Slaoui, M., Gaulton, G.N., Smith, T., Fields, B.N., Mullins, J. and Greene, M.I.: Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. Proc. Natl. Acad. Sci. (USA), 83:6578-6582, 1986.

117. Slaoui, M., Urbain-Vansanten, G., Demeur, C., Leo, O., Marvel, J., Moser, M., Tassignon, J., Greene, M.I. and Urbain, J.: Idiotypic Games Within the Immune Network. Immunological Reviews, 90:73-91, 1986.

118. Sandstrom, I.K., Foster, C.F., Wells, P.A., Knipe, D. and Greene, M.I.: Previous immmunization of mice with herpes simplex virus type-1 strain MP protects against secondary corneal infection. Clinical Immunology and Immunopathology, 40;326-334, 1986.

119. Foster, C.S., Tsai, Y., Monroe, J., Campbell, R., Cestari, M. Wetzig, R., Knipe, D. and Greene, M.I.: Genetic studies on murine susceptibility to herpes simplex keratitis. Clinical Immunology and Immunopathology, 40:313-325, 1986.

120. Dichter, M.A., Weiner, H.L., Fields, B.N., Mitchell, G., Noseworthy, J., Gaulton, G.N. and Greene, M.I.: Antiidiotypic Antibody to reovirus binds to neurons and protects from viral infection. Annals of Neurology, 19(6):555-558, 1986.

121. Gaulton, G.N. and Greene, M.I.: Anti-Idiotypic antibodies of reovirus as biochemical and immunological mimics. Intern. Rev. Immunology, 1:79-90, 1986.

122. Foster, C.S., Monroe, J.G., Campbell, R., Kalpaxis, J., Wetzig, R. and Greene, M.I.: Ocular Immune Responses. II. Priming of A/J mice in the vitreous induces either enhancement of or suppression of subsequent hapten-specific DTH responses. Journal of Immunology, 136(8):2787-2791, 1986.

123. Gaulton, G.N., Sharpe, A.H., Chang, D.W., Fields, B.N. and Greene, M.I.: Syngeneic monoclonal internal image anti-idiotopes as prophylactic vaccines. Journal of Immunology, 137: 2930-2936, 1986.

124. Drebin, J.A., Link, V.C., Weinberg, R.A. and Greene, M.I.: Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen Proc. Natl. Acad. Sci. (USA), 83:9129-9133, 1986.

125. Hashimoto, Y., Maxam, A.M. and Greene, M.I.: T-Cell antigen-receptor genes in autoimmune mice. Proc. Natl. Acad. Sci. (USA), 83:7865-7869, 1986.

126. Matsuzaki, N., Hinshaw, V.S., Fields, B.N. and Greene, M.I.: Cell receptors for the mammalian reovirus: Reovirus-specific T-cell hybridomas can become persistently infected and undergo autoimmune stimulation. Journal of Virology, 60(1):259-266, 1986.

127. Ventimiglia, R., Greene, M.I. and Geller, H.M.: Localization of β-adrenergic receptors on differentiated cells of the central nervous system in culture. Proc. Natl. Acad. Sci. (USA), 84:5073-5077, 1987.

128. Hashimoto, Y., Yui, K., Littman, D. and Greene, M.I.: T-cell receptor genes in autoimmune mice: T-cell subsets have unexpected T-cell receptor gene programs. Proc. Natl. Acad. Sci. (USA), 84:5883-5886, 1987.

129. Carroll, A.M. and Greene, M.I.: Anti-I-A antibody modulation of lymphocyte traffic in hapten-stimulated inbred mice. Immunology, 62:471-475, 1987.

130. Kokai, Y., Cohen, J.A., Drebin, J.A. and Greene, M.I.: Stage-and tissue-specific expression of the *neu* oncogene in rat development. Proc. Natl. Acad. Sci. (USA), 84:8498-8501, 1987.

131. Rubin, D.H., Costello, T., Witzleben, C.L. and Greene, M.I.: Transport of infectious reovirus into bile: Class II major histocompatibility antigen-bearing cells determine reovirus transport. Journal of Virology, 61(10):3222-3226, 1987.

132. Yui, K., Hashimoto, Y., Wadsworth S. and Greene, M.I.: Characterization of Lyt2$^-$-L3T4$^-$ class I-specific cytolytic clones in C3H-*gld/gld* mice. Implications for functions of accessory molecules and programmed development. Journal of Experimental Medicine, 166:1026-1040, 1987.

133. Greene, M.I., Kokai, Y., Gaulton, G.N., Powell, M.B., Geller, H. and Cohen, J.A.: Receptor systems in tissues of the nervous system. Immunological Reviews, 100:153-184, 1987.

134. Williams, W.V., Guy, H.R., Rubin, D.H., Robey, F., Myers, J.N., Kieber-Emmons, T., Weiner, D.B. and Greene, M.I.: Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: Modeling of their three-dimensional structures. Proc. Natl. Acad. Sci. (USA), 85:6488-6492, 1988.

135. Drebin, J.A., Link, V.C. and Greene, M.I.: Monoclonal anti-bodies specific for the *neu* oncogene product directly mediate anti-tumor effects *in vivo*. Oncogene, 2:387-394, 1988.

136. Drebin, J.A., Link, V.C., and Greene, M.I.: Monoclonal antibodies reactive with distinct domains of the *neu* oncogene-encoded p185 molecule exert synergistic anti-tumor effects *in vivo*. Oncogene, 2:273-278, 1988.

137. Yui, K., Hashimoto, Y. and Greene, M.I.: T cell receptors of autoimmune mice: Functional and molecular analysis of novel T cell subsets in C3H-gld/gld mice. Immunologic Research, 7:173-188, 1988.

138. Liu J., Co, M.S. and Greene, M.I.: Reovirus type 3 and [^{125}I]-Iodocyanopindalol bind to district domains on the Beta-Adrenergic like receptor. Immunologic Research, 7: 232-238, 1988.

139. Yui, K., Wadsworth, S., Yellen, A., Hashimoto, Y., Kokai, Y. and Greene, M.I. Molecular and functional properties of novel T cell subsets in C3H gld/gld and nude mice. Implication for thymic and extrathymic maturation. Immunological Reviews, 104:121-155, 1988.

140. Kokai, Y., Dobashi, K., Weiner, D.B., Nowell, P.C. and Greene, M.I.: Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular *neu (NGL)* gene products. Proc. Natl. Acad. Sci. (USA), 85:5389-5393, 1988.

141. Weiner, D.B., Liu, J., Hanna, N., Bluestone J.A., Coligan, J.E., Williams, W.V. and Greene, M.I.: CD3-associated heterodimeric polypeptides on suppressor hybridomas define biologically active inhibiting cells. Proc. Natl. Acad. Sci. (USA), 85:6077-6081, 1988.

142. Williams, W.V., Guy, H.R., Cohen, J.A., Weiner, D.B. and Greene, M.I.: Molecular and immunologic analyses of a functional internal image formed by an anti-receptor antibody. Ann. Institute Pasteur, 139:659-675, 1988.

143. Myers, J.N., Kokai, Y., Cohen, J.A. and Greene, M.I.: Monoclonal antibodies to oncogene encoded proteins. Immunologic modulation of cell growth, differentiation, and function. The Year in Immunology, 5: 178-194, 1988.

144. Williams, W.V., Weiner, D.B., Wadsworth, S., and Greene, M.I.: The antigen-major histocompatibility complex-T cell receptor interaction. Immunologic Research, 7:339-350, 1988.

145. Weiner, D.B., Williams, W.V., Siegel, R.M., Jerrold-Jones, S. and Greene, M.I.: Molecular characterization of suppressor T cells. Transplantation Proceedings, 6:1151-1153, 1988.

146. Greene, M.I.: Vaccine Development. Therapeutic Advances in Clinical Immunology, 8(1):169-178, 1988.

147. Gaulton, G.N. and Greene, M.I.: Inhibition of cellular DNA synthesis by reovirus occurs receptor-linked signaling pathway that is mimicked by antiidiotypic, antireceptor antibody. J. Exp. Med.,169:197-211, 1989.

148. Cohen, J.A., Weiner, D.B., More, K.F., Kokai, Y., Williams, W.V., Maguire, H.C., LiVolsi, V.A. and Greene, M.I.: Expression Pattern of the neu (NGL) gene-encoded growth factor receptor Protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene, 4:81-88, 1989.

149. Williams, W.V., Moss, D.A., Kieber-Emmons, T., Cohen, J.A., Myers, J.N., Weiner, D.B. and Greene, M.I.: Development of biologically active peptides based on antibody structure. Proc. Natl. Acad. Sci. (USA), 86:5537-5541, 1989.

150. Wadsworth, S., Yui, K. and Greene, M.I.: Major histocompatibility complex class I-specific cytolytic T cells, derived from *gld* mice, lacking Thy-1, CD4, and CD8. Proc. Natl. Acad. Sci. (USA), 86:1018-1022, 1989.

151. Weiner D.B., Liu J., Cohen J.A., Williams W.V. and Greene, M.I.: A point mutation in the neu oncogene mimics ligand induction of receptor aggregation Nature, 339:230-231, 1989.

152. Kokai, Y., Myers, J.N., Wada, T., Brown, V.I. LeVea, C., Davis, J.G., Dobashi, K. and Greene, M.I.: Synergistic Interaction of p185c-*neu* and the EGF receptor leads to transformation of rodent fibroblasts. Cell, 58:287-292, 1989.

153. Dobashi, K., Weiner, D.B. and Greene, M.I.: Differential regulation of oncogenic and cellular p185 by serine/threonine kinases. DNA and Cell Biology, 8(10):723-732, 1989.

154. Weiner, D.B., Kokai, Y., Wada, T., Cohen, J.A., Williams, W.V. and Greene, M.I.: Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene, 4, 1175-1183, 1989.

155. Maguire, H.C. and Greene, M.I.: The *neu* (cerbB-2) oncogene. Seminars in Oncology, 16(2):148-155, 1989.

156. Williams, W.V., London, S.D., Weiner, D.B., Wadsworth, S., Berzofsky, J.A., Robey, F., Rubin, D.H. and Greene, M.I.: Immune response to a molecularly defined internal image idiotope. J. of Immunology, 142(11):4392-4400, 1989.

157. Romano C., Williams W.V., Fischberg D.J., Cocero N., Weiner D.B., Greene M.I and Molinoff, P.: Subtype-selective immunoprecipitaion of the β_2-adrenergic receptor. Journal of Neurochemistry, 53(2),362-369, 1989.

158. Cohen, J.A., Williams, W.V., Weiner, D.B., Geller, H.M. and Greene, M.I. Ligand binding to the cell-surface receptor for reovirus type 3 stimulates galactocerebroside expression by developing oligodendrocytes. Proc Natl Acad Sci. (USA), 87:4922-4926, 1990.

159. Wadsworth, S., Yui, K. Siegel R., Tenenholz, D.E., Hirsch, J.A. and Greene, M.I.: Origin and selection of peripheral $CD4^{-}CD8^{-}$ T cells bearing T cell antigen receptors in autoimmune *gld* mice. European Journal of Immunology, 20:723-730, 1990.

160. Siegel R., Yui K., Tenenholz D., Kubo R. and Greene M.I.: Inhibition of T cell development in thymic organ culture. Implications for the mechanism of action of cyclosporin A. European Journal of Immunology, 20:753-757, 1990.

161. Wada T., Myers, J.N., Kokai Y., Brown, V.I., Hamuro, J., LeVea C.M. and Greene M.I: Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins. Oncogene, 5:489-495, 1990.

162. Hashimoto Y., Maxam A.M. and Greene M.I: Identification of tissue specific nuclear proteins: DNA sequence and protein binding regions in the T cell receptor beta J-C intron. Nucleic Acids Research, 18(10):3027-3033, 1990.

163. Yui K., Komori S., Katsumata M., Siegel R.M. and Greene M.I.: Self-reactive T cells can escape clonal deletion in T-cell receptor Vβ8.1 transgenic mice. Proc. Natl Acad. Sci. (USA), 87:7135-7139, 1990.

164. Wada T, Qian X. and Greene M.I.: Intermolecular association of the $p185^{neu}$ protein and EGF receptor modulates EGF receptor function. Cell, 61,1339-1347, 1990.

165. Siegel R., Katsumata M., Komori S., Wadsworth, S., Gill-Morse, L., Jerrold-Jones, S., Bhandoola, A., Greene, M.I. and Yui, K.: Mechanisms of autoimmunity in the context of T-cell tolerance. Insights from natural and transgenic animal model systems. Immunologic Reviews, 118:165-192, 1990.

166. Weiner D.B., Nordberg J., Nowell P.C., Gazdar A., Greene M.I. Willliams W.W. Cohen J.,and Kern J.A., Expression of the neu gene encoded protein p185neu in human non small cell carcinomas of the lung. Cancer Research 1990; 50:421-425.

167. Williams, T.M., Weiner, D.B., Greene, M.I. and Maguire, H.C. Jr.: Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology, 59:46-52, 1991.

168. Kern, J.A., Schwartz, D.A., Norberg, J.E., Weiner, D.B., Greene, M.I., Torney, L., and Robinson, R.A. $p185^{neu}$ Expression in Human Lung Adenocarcinomas Predicts Shortened Survival. Cancer Research, 50: 5184-5191, 1990.

169. Cohen, J.A., Williams, W.V, Geller, H.M. and Greene, M.I.: Anti-reovirus receptor antibody accelerates expression of the optic nerve oligodendrocyte developmental program. Proc.Natl Acad. Sci. (USA), 88:1266-1270, 1991.

170. Williams W.V., Kieber-Emmons, T., Weiner, D.B., Rubin, D.H.,and Greene M.I.: Contact residues and predicted structure of the reovirus type 3-receptor interaction. Journal of Biological Chemistry, 266(14):9241-9250, 1991.

171. Turner, B., Rapp, U., App, H., Greene, M.I., Dobashi, K. and Reed, J.C.: Interleukin 2 induces tyrosine phosphorylation and activation of p72-74 Raf-1 kinase in a T cell line. Proc. Nat'l. Acad. Sci. (USA), 88:1227-1231, 1991.

172. Weiner, D.B., Huebner, K., Williams, W.V. and Greene, M.I.: Human genes other than CD4 facilitate HIV-1 infection of murine cells. Pathobiology, 59:361-371, 1991.

173. Dobashi, K, Davis, J.G., Mikami, Y., Freeman, J.K., Hamuro, J. and Greene, M.I.: Characterization of a neu/c-erbB-2 protein-specific activating factor. . Proc. Nat'l. Acad. Sci. (USA), 88:8582-8586, 1991.

174. Williams, W.V., Kieber-Emmons, T., VonFeldt, J., Greene, M.I. and Weiner, D.B.: Design of bioactive peptides based on antibody hypervariable region structures. Journal of Biological Chemistry, 266(8):5182-5190, 1991.

175. Saragovi, U., Fitzpatrick, D., Raktabuhr, A., Nakanishi, H., Kahn, M. and Greene, M.I.: Design and synthesis of a mimetic from an antibody complementarity-determining region. Science, 253:792-795, 1991.

176. Davis, J.G., Hamuro, J., Shim, C.Y., Samanta, A., Greene, M.I. and Dobashi, K.: Isolation and characterization of a neu protein-specific activating factor from human ATL-2 cell conditioned medium. Biomedical and Biophysical Research Communications, 179(3): 1536-1542, 1991.

177. Myers, J.N., LeVea, C.M., Smith, J.E., Kallen, R.G., Tung, L. and Greene, M.I.: Expression, purification, and characterization of bacneu. Receptor, 2:1-16, 1992.

178. Qian, X., Decker, S. and Greene, M.I.: $p185^{c\text{-}neu}$ and epidermal growth factor receptor associate into a structure composed of activated kinases. Proc. Nat'l. Acad. Sci. (USA), 89:1330-1334, 1992.

179. Yui, K. and Greene, M.I.: $CD4^{-}CD8^{+}$ T-cell receptor-□□ major histocompatibilty complex class-II-specific T-cell clones isolated from aged athymic mice. Immunological Research, 11:3-10, 1992.

180. Yui, K., Katsumata, M., Komori, S., Gill-Morse, L. and Greene, M.I.: Response of Vβ 8.1^{+} T cell clones to self MIs-1^{a}: implications for the origin of autoreactive T cells. International Immunology, 4(2):125-133, 1992.

181. Chen, S, Chrusciel, R.A., Nakanishi, H, Raktabutr, A., Johnson, M.E., Sato, A., Weiner, D., Hoxie, J., Saragovi U., Greene M.I. and Kahn, M.: Design and synthesis of a CD4 β-turn mimetic that inhibits human immunodeficiency virus viral envelope glycoprotein gp120 binding and infection of human lymphocytes. Proc. Natl. Acad. Sci. (USA), 89:5872-5876, 1992.

182. Williams, W.V., Weiner, D.B., Borofsky, M.A., Rubin, D.H., Yui, K. and Greene, M.I.: Modulation of T cell responses with MHC-derived peptides. Immunologic Research, 11:11-23, 1992.

183. Mikami, Y., Davis, J.G., Dobashi, K., Dougall, W.C., Myers, J.N., Brown, V.I. and Greene, M.I.: Carboxy-terminal deletion and point mutations decrease the transforming potential of the activated rat *neu* oncogene product. Proc. Natl. Acad. Sci. (USA), 89:7335-7339, 1992.

184. Siegel, R.M., Katsumata, M., Miyashita, T., Louie, D.C., Greene, M.I. and Reed, J.C.: Inhibition of thymocyte apoptosis and negative antigenic selection in *bcl*-2 transgenic mice. Proc. Natl. Acad. Sci. (USA), 89:7003-7007, 1992.

185. Saragovi, H.U, Kahn, M.E., Chrusciel, R.A. and Greene M.I.: Loops and Secondary Structure Mimetics: Development and Applications in Basic Science and Rational Drug Design. Nature, 10:773-778, 1992.

186. Taub, R. and Greene, M.I.: Functional validation of ligand mimicry by anti-receptor antibodies: Structural and therapeutic implications. Biochemistry,. 31:7431-7435, 1992.

187. Maguire, H.C. Jr., Hellman, M.E., Greene, M.I. and Yeh, I.: Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast. Pathobiology, 60:117-121, 1992.

188. Yui, K., Bhandoola, A., Radic, M.Z., Komori, S., Katsumata, M. and Greene, M.I.: Inhibition of abnormal T cell development and autoimmunity in gld mice by transgenic T cell receptor chain. Eur. J. Immunology, 22: 1693-1700, 1992.

189. Saragovi, H.U. and Greene, M.I., Constrained peptides and mimetics as probes of protein secondary structure. Immunomethods, 1:1-5, 1992.

190. Katsumata, M., Siegel, R.M., Louie, D.C., Miyashita, T., Tsujimoto, Y., Nowell, P.C., Greene, M.I. and Reed, J.C.: Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc. Nat'l. Acad. Sci. (USA), 89: 11376-11380, 1992.

191. Cohen, J.A., Sergott, R.C., Williams, W.V., Hill, S.J., Brown, M.J. and Greene, M.I. In vivo modulation of oligodendrocyte function by an anti-receptor antibody. Pathobiology, 60:151-156, 1992.

192. Rubin, D.H., Weiner, D.B., Dworkin, C., Greene, M.I., Maul, G.G. and Williams, W.V. Receptor utilization by reovirus type 3: Distinct binding sites on thymoma and fibroblast cell lines result in differential compartmentalization of virions. Microbial Pathogenesis, 12:351-365, 1992.

193. Weiner, D.B., Williams, W.V., Weisz, P.B., and Greene, M.I. Synthetic Cyclodextrin Derivatives Inhibit HIV Infection in vitro. Pathobiology, 60: 206-212, 1992.

194. Ugen, K. E., McCallus, D.E., Von Feldt, J. M., Williams, W.V., Greene, M.I., and Weiner, D.B. Ocular Tissue Involvement in HIV Infection: Immunological and Pathological Aspects. Immunologic Research 11: 141-153, 1992.

195. Cohen, J.A., Baggott, L.A., Romano, C., Arai, M., Southerling, T., Young, L.H., Kozak, C.A., Molinoff, P.B. and Greene, M.I.: Characterization of a mouse ß1-adrenergic receptor genomic clone. DNA and Cell Biology, 12(6):537-547, 1993.

196. Sauvé, G.J., Saragovi, H.U. and Greene, M.I.: Reovirus Receptors. Advances in Virus Research, 42:325-341, 1993.

197. LeVea, C.M., Myers, J.N., Dougall, W.C., Qian, X. and Greene, M.I.: A Structural and kinetic comparison of proto-oncogenic and oncogenic neu holo-receptors expressed in insect cells. Receptor, 3:293-309, 1993.

198. Bhandoola, A., Cho, E.A., Yui, K., Saragovi, H.U., Greene, M.I. and Quill, H.: Reduced CD3-mediated protein tyrosine phosphorylation in anergic $CD4^+$ and $CD8^+$ T cells. J. Immunology 151(5):2355-2367, 1993.

199. Komori, S., Katsumata, M., Greene, M.I. and Yui, K.: Frequent deletion of the transgene in T cell receptor β chain transgenic mice. International Immunolology, 5(2):161-167, 1993.

200. Dougall, W.C., Qian, X. and Greene, M.I.: Interaction of the Neu/p185 and EGF receptor tyrosine kinases: Implications for cellular transformation and tumor therapy. Journal of Cellular Biochemistry, 53:61-73, 1993.

201. Jardines, L., Weiss, M., Fowble, B. and Greene, M.I.: neu(c-*erb*B-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology, 61:268-282, 1993.

202. Bhat, T.N., Bentley, G.A., Boulot, G., Greene, M.I., Tello, D., Acqua, W.D., Souchon, H., Schwartz, F.P., Mariuzza, R.A. and Poljak, R.J.: Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc. Nat'l Acad. Sci. (USA), 91:1089-1093, 1994.

203. Saouaf, S.J., Zerva, L., and Greene, M.I.: Peripheral Tolerance to the Azobenzenearsonate Hapten in Vα3.1 T Cell Receptor Transgenic Mice. Transgenics, 1: 171-183, 1994.

204. Saouaf, S.J., Katsumata, M., Yui, K., Thayu, S., Gascoigne, R.J. and Greene, M.I.: Azobenzenearsonate hapten specific T cell receptor alpha chain transgenic mice. Transgenics, 1:185-201,1994.

205. Qian, X., LeVea, M., Freeman, J., Dougall, W.C. and Greene, M.I.: Heterodimerization of epidermal growth factor receptor and wild type or kinase-deficient Neu: A Mechanism of interreceptor kinase activation and transphosphorylation. Proc. Natl. Acad. Sci. (USA), 91:1500-1504, 1994.

206. Samanta, A., LeVea, C.M., Dougall, W.C., Qian, X. and Greene, M.I.: Ligand and $p185^{c\text{-}neu}$ density govern receptor interactions and tyrosine kinase activation. Proc. Nat'l Acad. Sci. (USA), 91:1711-1715, 1994.

207. Siegel, R.M., Katsumata, M., Lang, M., Reed, J.C. and Greene, M.I.: Repertoire selection and kinetics of T-cell development in transgenic mice overexpressing *BCL*-2. Transgenics, 1:155-162, 1994.

208. Qian, X., Dougall, W.C., Hellman, M. and Greene, M.I.: Kinase-deficient *neu* proteins suppress epidermal growth receptor function and abolish cell transformation. Oncogene, 9:1507-1514, 1994.

209. Dougall, W.C., Peterson, N.C. and Greene, M.I.: Antibody-structure-based design of pharmacological agents. Trends in Biotechnology, 12: 372-379, 1994.

210. Brown, V.I., Shah, N., Smith, R., Hellman, M., Jarett, L., Mikami, Y., Cohen, E., Qian, X. and Greene, M.I.: Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor. DNA and Cell Biology, 13(2): 193-209, 1994.

211. Saouaf, S.J., Zerva, L. and Greene, M.I.: Peripheral tolerance to the azobenzenearsonate hapten in Vα3.1 T cell receptor transgenic mice. Transgenics, 1: 171-183, 1994.

212. Bhandoola, A., Bassiri, H., Markmann, J.F., Yui, K., Hashimoto, Y. and Greene, M.I.: Delayed allograft rejection by T cell receptor Vβ8.1 transgenic mice peripherally tolerized to Mls-1^a. European Journal of Immunology, 24:1710-1713, 1994.

213. Dougall, W.C., Qian, X., Peterson, N.C., Miller, M.J., Samanta, A. and Greene, M.I.: The *neu*-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene, 9: 2109-2123, 1994.

214. Peterson, N.C. and Greene, M.I.: Considerations in the design and production of small anti-receptor antibody Forms: Optimizing gains while reducing size. Therapeutic Immunology, 1:289-295, 1994.

215. Bhandoola, A., Markmann, J.F., Son, C.B. Bassiri, H., Yui, K. and Greene, M.I: Defective allograft rejection in TcR Vβ8.1 transgenic mice provides an explanation for improvement of lymphadenopathy in TcR transgenic gld and lpr mice. Transgenics, 1:459-463, 1995.

216. Samanta, A., Qian, X. and Greene, M.I.: Unexpected transcriptional signals in normal and mitotically defective cells mediated through cytokine and growth factor receptors. DNA and Cell Biology, 14(11):921-930, 1995.

217. Stieber, A., Chen, Y., Gonatas, J., Dougall, W., Qian, X., O'Rourke, D., Samanta, A., Greene, M.I. and Gonatas, N.K.: Identification of a 140kDa protein of rat presynaptic terminal membranes encompassing the active zones. Brain Research, 700:261-270, 1995.

218. Davis, J.G., Oberholtzer, J.C., Burns, F.R. and Greene, M.I.: Molecular cloning and characterization of an inner ear-specific structural protein. Science, 267: 1031-1034, 1995.

219. Saragovi, H.U., Bhandoola, A., Lemercier, M., Akbar, G.K.M. and Greene, M.I.: A receptor that subserves reovirus binding can inhibit lymphocyte proliferation triggered by mitogenic signals. DNA and Cell Biology,14(8): 653-664, 1995.

220. Qian, X., Dougall, W.C., Fei, Z. and Greene, M.I.: Intermolecular association and trans-phosphorylation of different *neu*-kinase forms permit SH2-dependent signaling and oncogenic transformation. Oncogene, 10:211-219, 1995.

221. Oshima, M., Weiss, L., Dougall, W.C., Greene, M.I. and Guroff, G.: Down-regulation of c-*neu* receptors by nerve growth factor in PC12 cells. Journal of Neurochemistry, 65(1):427-433, 1995.

222. Katsumata, M., Okudaira, T., Samanta, A., Clark, D.P., Drebin, J.A., Jolicoeur, P. and Greene, M.I.: Prevention of breast tumor development *in vivo* by downregulation of the $p185^{neu}$ receptor. Nature (Medicine), 1(7):644-648, 1995.

223. Shinto, Y., Morimoto, M., Katsumata, M., Uchida, A., Aozasa, K., Okamoto, M., Kurosawa, T., Ochi, T., Greene, M.I. and Tsujimoto, Y.: Moloney murine leukemia virus infection accelerates lymphomagenesis in Eμ-*bcl*-2 transgenic mice. Oncogene, 11:1729-1736, 1995.

224. Lescar, J., Pellegrini, M., Souchon, H., Tello, D., Poljak, R.J., Peterson, N., Greene, M.I. and Alzari, P.M.: Crystal structure of a cross-reaction complex between Fab F9.13.7 and guinea-fowl lysozyme. Journal of Biological Chemistry, 270(30):18067-18076, 1995.

225. Davis J.G., Oberholtzer, J.C., Burns, F.R., Lee, A.M., Saunders, J., Eberwine, J.H. and Greene, M.I.: Use of the teleost saccule to identify genes involved in inner ear function. DNA and Cell Biology, 14(10):833-839, 1995.

226. Samanta, A. and Greene, M.I.: A kinase associated with chromatin that can be activated by ligand-p185$^{c\text{-}neu}$ or epidermal growth factor-receptor interactions. Proc. of the Nat'l Acad. of Sci. (USA), 92:6582-6586, 1995.

227. Dougall, W.C., Qian, X., Miller, M.J. and Greene, M.I.: Association of signaling proteins with a non-mitogenic heterodimeric complex composed of epidermal growth factor receptor and kinase-inactive p185$^{c\text{-}neu}$. DNA and Cell Biology, 15(1):31-40, 1996.

228. Zhang, X., Piatier-Tonneau, D., Auffray, C., Murali, R., Mahapatra, A., Zhang, F., Maier, C.C., Saragovi, H.U. and Greene, M.I.: Synthetic CD4 excocyclic peptides antagonize CD4 holoreceptor binding and T cell activation. Nature (Biotechnology), 14:472-475, 1996.

229. Rebai, N., Almazan, G., Wei, L., Greene, M.I. and Saragovi, H.U.: A p65/p95 neural surface receptor is expressed at the S-G2 phase of the cell cycle and defines distinct populations. European Journal of Neuroscience, 8:273-281, 1996.

230. Sim, B-C., Zerva, L., Greene, M.I. and Gascoigne, N.R.J.: Control of MHC restriction by TCR VαCDR1 and CDR2. Science, 273:963-966, 1996.

231. Lee, A.M., Navaratnam, K., Ichimiya, S., Greene, M. I. and Davis, J. G.: Cloning of m-ehk2 from the murine inner ear, an eph family receptor tyrosine kinase expressed in the developing and adult cochlea. DNA and Cell Biology, 15(10):817-825, 1996.

232. Murali, R., Brennan, P.J., Kieber-Emmons, T., and Greene, M.I.: Structural analysis of p185$^{c\text{-}neu}$ and epidermal growth factor receptor tyrosine kinases: Oligomerization of kinase domains Proc. of the Nat'l Acad. of Sci. (USA), 93: 6252-6257, 1996.

233. Qian, X., O'Rourke, D.M., Zhao, H. and Greene, M.I.: Inhibition of p185^{neu} kinase activity and cellular transformation by co-expression of a truncated neu protein. Oncogene, 13:2149-2157, 1996.

234. O'Rourke, D.M., Qian, X., Zhang, H.T., Davis, J., Nute, E., Meinkoth, J. and Greene, M.I.: Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains. Proc. of the Nat'l Acad. of Sci. (USA), 94:3250-3255, 1997.

235. Zhang, H.T., Zhang, X., Zhao, H.-Z., Kajino, Y., Weber, B.L., Davis, J.G., Wang, Q., O'Rourke, D.M., Zhang, H.-B. and Greene, M.I.: Relationship of p215^{BRCA1} to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells. Oncogene, 14:2863-2869, 1997.

236. Davis, J.G., Burns, F.R., Navaratnam, D., Lee, A.M., Ichimiya, S., Oberholtzer, J.C. and Greene, M.I.: Identification of a structural constituent and one possible site of postembryonic formation of the teleost otolithic membrane. Proc. of the Nat'l Acad. of Sci. (USA), 94: 707-712, 1997.

237. Zhang, X., Gaubin, M., Briant, L., Srikantan, V., Murali, R., Saragovi, H.U., Weiner, D., Devaux, C., Piatier-Tonneau, D. and Greene, M.I.: Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes. Nature (Biotechnology), 15:150-154, 1997.

238. Ichimiya, S., Davis, J.G., O'Rourke, D.M., Katsumata, M. and Greene, M.I.: Murine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of brain most susceptible to hypoxic and ischemic injury. DNA and Cell Biology, 16(3):311-321, 1997.

239. Takasaki, W., Kajino, Y., Kajino, K., Murali, R. and Greene, M.I.: Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF□ binding to its receptor. Nature (Biotechnology), 15:1266-1270, 1997.

240. Kieber-Emmons, T., Murali, R. and Greene, M.I.: Therapeutic peptides and peptidomimetics. Current Opinion in Biotechnology, 8:435-441, 1997.

241. Briant, L., Signoret, N., Gaubin, M., Robert-Hebmann, V., Zhang, X., Murali, R., Greene, M., Piatier-Tonneau, D. and Devaux, C.: Transduction of Activation Signal That Follows HIV-1 Binding to CD4 and CD4 Dimerization Involves the Immunoglobulin CDR3-like Region in Domain 1 of CD4. Journal of Biological Chemistry, 272(31): 19441-19450, 1997.

242. Saragovi, H.U., Rebai, N., Roux, E., Gagnon, M., Zhang, X., Robaire, B., Bromberg, J. and Greene, M.I.: Signal transduction and antiproliferative function of the mammalian receptor for type 3 reovirus. Current Topics in Microbiology and Immunology, 7:155-166, 1998.

243. Qian, X., O'Rourke, D.M., Drebin, J., Zhao, H., Wang, Q. and Greene, M.I.: Identification of $p185^{neu}$ sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation. DNA and Cell Biology, 16(12):1395-1405, 1998.

244. Maier, C.C., Bhandoola, A., Borden, W., Yui, K., Hayakawa, K. and Greene, M.I.: Unique molecular surface features of *in vivo* tolerized T cells. Proc. of the Nat'l Acad. of Sci. (USA), 95,4499-4503, 1998.

245. Zhang, H.T., O'Rourke, D., Zhao, H., Murali, R., Mikami, Y., Davis, J.G., Greene, M.I. and Qian, X.: Absence of autophosphorylation site Y882 in the $p185^{neu}$ oncogene product correlates with a reduction of transforming potential. Oncogene, 16:2835-2842, 1998.

246. O'Rourke, D., Nute, E.J.L., Davis, J.G., Wu, C., Lee, A., Murali, R., Zhang, H.T., Qian, X., Kao, C.C. and Greene, M.I.: Inhibition of a naturally occurring EGFR oncoprotein by the p185*neu* ectodomain: implications for subdomain contributions to receptor assembly. Oncogene, 16:1197-1207, 1998.

247. Wang, Q., Zhang H.T., Kajino K. and Greene M.I.: BRCA1 binds c-myc and inhibits its transcriptional and transforming activity in cells. Oncogene, 17:1939-1948, 1998.

248. O'Rourke, D., Kao, G.D., Singh, N., Park, B., Muschel, R.J., Wu, C. and Greene, M.I.: Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc. of the Nat'l Acad. of Sci. (USA), 95:10842-10847, 1998.

249. Peterson, N. and Greene, M.I.: Bacterial expression and characterization of recombinant biologically-active anti-tyrosine kinase receptor antibody forms. DNA and Cell Biology, 17(12):1031-1040, 1998.

250. Qian, X., O'Rourke, D.M., Fei, Z., Zhang, H., Kao, C. and Greene, M.I.: Domain-specific interactions between the $p185^{neu}$ and epidermal growth receptor kinases determine differential signaling outcomes. Journal of Biological Chemistry, 274(2):574-583, 1999.

251. Park, B., O'Rourke, D., Wang, Q., Davis, J., Post, A., Qian, X. and Greene, M.I.: Induction of the Tat-binding protein-1 accompanies the disabling of oncogenic erbB receptor tyrosine kinases. Proc. of the Nat'l Acad. of Sci. (USA), 96:6434-6438, 1999.

252. Kajino, Y., Kajino, K., Yui, K. and Greene, M.I.: Unusual Patterns of Lysis ofFas Ligand Defective T Cell Clones Derived from gld/gld mice Suggest a Role of Thy-1 in Triggering Some Forms of Cytotoxicity. Transgenics,3:107-119, 1999.

253. Zhang, H., Wang, Q., Montone, K., Peavey, J., Drebin, J.A., Greene, M.I. and Murali, R.: Shared antigenic epitopes and pathobiological functions of anti-$p185^{her2/neu}$ monoclonal antibodies. Experimental and Molecular Pathology, 67:15-25, 1999.

254. Saragovi, H.U., Rebai, N., Di Guglielmo, G.M., Macleod, R., Sheng, J., Rubin, D.R., and Greene, M.I: A G_1 cell cycle arrest induced by ligands of the reovirus type 3 receptor is secondary to inactivation of $p21^{ras}$ and mitogen-activated protein kinase. DNA and Cell Biology, 18: 763-770, 1999.

255. Roland, J., Berezov, A., Greene, M.I., Murali, R., Piater-Tonneau, D., Devaux, C., Briant, L: The synthetic CD4 exocyclic CDR3.AME(82-89) inhibits NK-□B nuclear translocation, HIV-1 promoter activation, and viral gene expression. DNA and Cell Biology,11:819-828, 1999.

256. Zhang, H., Wang, Q., Kajino, K. and Greene, M.I.: VCP, a weak ATPase involved in multiple cellular events, physically interacts with BRCA1 in the nucleus of living cells. DNA and Cell Biology, 19, 5: 253-263, 2000.

257. Wu, C., Chen, Z., Ullrich, A., Greene, M.I., O'Rourke, D.:Inhibition of EGFR-mediated phosphoinositide-3-OH (PI3-K) signaling and glioblastoma phenotype by Signal-Regulatory Proteins (SIRPs). Oncogene, 19,3999-4010, 2000.

258. Matsunaga, T., Greene, M.I. and Davis, J.G.: Distinct expression patterns of Eph receptors and ephrins relate to the structural organization of the adult rate peripheral vestibular system. European Journal of Neuroscience, 12: 1-18, 2000.

259. Park, B.W., Berezov, A., Wu, C.W., Zhang, X., Dua, R., Zhang, H.T., Wang, Q., Kao, G., O'Rourke, D., Greene, M.I. and Murali, R.: Rationally designed anti-HER2/neu peptide mimetic disables $p185^{HER2/neu}$ tyrosine kinases *in vitro* and *in vivo*. Nature (Biotechnology), 18: 194-198, 2000.

260. Maeda, H., Fujimoto, S., Greene, M.I.: Suppressor T Cells Regulate the Non Anergic Cell Population That Remains after Peripheral Tolerance is Induced to the Mls-1 Antigen in TCR VB8.1 Transgenic Mice. Proc. Natl. Acad. Sci., 97: 13257-13262, 2000.

261. Brennan, P. J., Kumogai, T., Berezov, A., Murali, R., and Greene, M.I. HER2/Neu: mechanisms of dimerization/oligomerization, Oncogene, 19: 6093-6101, 2000.

262. Wang, Q., Zhang, H., Fishel, R. and Greene, M.E. BRCA1 and Cell Signaling, Oncogene, 19:6152-6158, 2000.

263. Kumagai, T., Davis, J.G., Horie, T., O'Rourke, D., and Greene, M.I. The role of distinct p185 extracellular subdomains for dimerization with the epidermal growth factor receptor and EGF mediated signaling, Proc. Natl. Acad. Sci., 98:5526-5531, 2001.

264. Zhang, H.T., Kacharmina, J.E., Miyashiro, K., Greene, M.I., and Eberwine, J. Protein Quantification from Complex Protein Mixtures Using a Novel Proteomics Methodology with Single Cell Resolution, Proc. Natl. Acad. Sci., 98:5497-5502, 2001.

265. Matsunaga, T., Davis, J.G., Greene, M.I. Adult rat otic placode-derived neurons and sensory epithelium express all four erbB receptors: A role in regulating vestibular ganglion neuron viability, DNA and Cell Biology, 20:307-319, 2001

266. Berezov, A., Zhang, H.T., Murali, R., Greene, M.I.: Disabling ErbB Receptors with Rationally Designed Exocyclic Mimetics of Antibodies: Structure-Function Analysis, Journal of Medicinal Chemistry, 44:2565-2574, 2001.

267. Wang, Q., Zhang, H., Guerrette, S., Mazurek, A., Wilson, T., Kajino, K., Fischel, R. and Greene, M.I.:Adenosine nucleotide modulated interaction between hMSH2 and BRCA1. Oncogene., 20:4640-4649, 2001.

268. Wu, C., O'Rourke, D. M., Feng, G., Johnson, G.R., Wang, Q., and Greene, M.I. The Tyrosine Phosphatase SHP-2 is Required for Mediating Phosphatidylinositol 3-Kinase/Akt Activatyion by Growth Factors, Oncogene., 20:6018-6025, 2001.

269. Murayama, E., Takagi, Y., Ohiro, T., Davis. J.G., Greene, M.I., and Nagasawa, H. Fish otolith contains a unique structural protein, otolin-1, European Journal of Biochemistry, 269: 688-696, 2002.

270. Cowan, D.A., Gay, D., Bieler, B. M., Zhao, H. Yoshino, A., Davis, J.G., Tomayko, M. M., Murali, R., Greene, M. I., and Marks, M. S. Characterization of mouse tGolgin-1 (golgin-245/trans golgi p230/256kD golgin) and its upregulation during oligodendrocyte development, DNA and Cell Biology, 21 (7): 505-517, 2002.

271. Berezov, A., Chen, J., Liu, Q., Zhang, H., Murali, R., and Greene, M.I. Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics, The Journal of Biological Chemistry, 277:28330-28339, 2002.

272. Horie, T., Shen, Yuan, Kajino, K., Gaubin, M., Bonomi, G., Mani, J.-C., Berezov, A., Piatier-Tonneau, D., Guardiola, J.,Hillard, B., Rostami, A., Greene, M. I., and Murali, R. Study of disabling T-cell activation and inhibiting T-cell mediated immunopathology reveals a possible inverse agonist activity of CD4 peptidommimetics, Experimental and Molecular Pathology, 73:93-103, 2002.

273. Cheng, X., Kinosaki, M., Murali, R., and Greene, M.I. The TNF Receptor Superfamily: Role in Immune Inflammation and Bone Formation, Immunologic Research: 27: 287-294, 2003.

274. Kumagai, T., Katsumata, M., Hasegawa, A., Funakoshi, T., Kawase, I., and Greene, M.I. Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor (EGFR) in ligand-independent association and ligand-induced transactivation. Proc. Natl. Acad. Sci., 100: 9220-9225, 2003.

275. Murali, R., Liu, Q., Cheng, X., Berezov, A., Richter, M., Furuuchi, K., Greene, M. I:, and Zhang, H. Antibody like peptidomimetics as large scale immunodetection probes. Cell and Molecular Biology, 49, 209-216, 2003.

276. Zhang, H.T., Richter, M., and Greene, M.I. Therapeutic monoclonal antibodies for the erbB family of receptor tyrosine kinases. Cancer Biology and Therapy 1, 90-96, 2003.

277. Brennan, P. J., Saouaf, S. J., Greene, M. I., and Shen, Y. Anergy and Suppression as Coexistent Mechanisms for the maintenance of Peripheral T Cell Tolerance. Immunologic Research, 27 (2-3), 295-302, 2003.

278. Berezov, A., Greene, M.I., Murali, R. Structure-Based Approaches to Inhibition of erbB Receptors with Peptide Memetics. Immunologic Research, 27 (2-3): 303-308, 2003.

279. Saouaf, S. J., Brennan, P. J., Shen, Y., Greene, M. I. Mechanisms of Peripheral Immune Tolerance. Immunologic Research, 28/3: 193-199, 2003.

280. Hasegawa, A., Cheng, X., Kajino, K., Berezov, A., Murata, K., Nakayama, T., Yagita, H., Murali,R., and Greene, M. I. Fas Disabling Small Exocyclic Peptide Mimetics Limit Apoptosis by an Unexpected Mechanism. Proc. Natl. Acad. Sci., 101:6599-6604, 2004.

281. Zhang, H., Cheng, X., Richter, M., and Greene, M. I. A simple and ultra sensitive antigen detection system. Nature (Methods), in press, 2004.

282. Wang, Q., Furuuchi, K., Hirohashi, Y., Zhao, H., Liu, Q., Zhang, H., Murali, R., Berezov, A., Du, X., Li, B., and Greene, M. I. The Centrosome in Normal and Transformed Cells. DNA and Cell Biology, in press, 2004.

283. Wang, Q and Greene MI. Molecular mechanisms that lead to aneuploidy/tetraploidy in erbB transformed cells. In preparation 2004

284. Murali, R., Freire, E., Milstein, S. Cheng X., and Greene, M.I. Cavity Induced Allosteric Modification: A structure based approach to inhibitor design. In preparation, 2004.

Books and Monographs:

1. Fujimoto, S., Greene, M., Sehon, A.H. Immunosuppressor T cells and their factors in tumor bearing hosts. In: Singal, SK, Sinclair, NRSTC, eds. Suppressor cells in Immunity. University of Western Ontario Press, 1975.

2. Greene, M.I. Suppressor T cell and their factors in the S1509a tumor bearing A/Jax mouse host. Ph.D. Thesis, University of Manitoba, 1977.

3. Greene, M.I., Fujimoto, S. Sehon, A. The characterization of thymic suppressor factor(s) regulating the immune response to tumor antigen. In: XXVth Protides of the biological fluids. Pergamon Press, 1978.

4. Greene, M.I., Bach, B.A., Sy, M.S., Brown, A.R., Nisonoff, A., Benacerraf, B. Antigen and receptor stimulated regulation. The relationship of idiotype and MHC products to regulatory networks. In: Bach F., Bonavida, B., Vitetta E., Eds. T and B lymphocytes: Recognition and Function. 1979 ICN-UCLA Symposium. New York: Academic Press, 1979:361-372.

5. Greene, M.I., Perry, L.L., Benacerraf, B. The mechanism and genetic basis of the immune response to tumor antigen. In: Kilburn, G., Levy, J.G., Teh, H.S., eds. Regulation of the immune response. University of British Columbia Press, 1979:114-130.

6. Nisonoff, A., Sy, M.S., Dohi, Y., Bach, B.A., Brown, A.B., Benacerraf, B., Greene, M.I. Antigenica in idiotypic regulation of humoral and cellular immune responses. In: Kilburn, G. Levy, J.G., Teh, H.S., eds. Regulation of the Immune Response. University of British Columbia Press, 1979:324-346.

7 Greene, M.I. The regulation of syngeneic tumor immunity. In: Warner, N. ed. 7. Contemporary topics in immunobiology. Plenum Press, 1980:81-110.

8. Greene, M.I. Tumor immunity and the major histocompatibility complex In: Dorf, M.E., ed. Role of the major histocompatibility complex in immunobiology. Garland Press, 1981.

9. Vadas, M.A., Greene, M.I. Role of the major histocompatibility complex in delayed type hypersensitivity. In: Dorf, M.E., ed. Role of the major histocompatibility complex in immunobiology. Garland Press, 1981.

10. Abbas, A.K., Gefter, M.L., Greene, M.I. Regulation of myeloma cells by idiotype reactive suppressor T lymphocytes. In: Klinman, N., Mosier, D., Scher, I., Vitetta, eds. B lymphocytes in the immune response. North Holland: Elsevier Press, 1981:523-530.

11. Greene, M.I., Bromberg, J.S., Nepom, J.T., Finberg, R., Rock, K., Whitaker, B., Germain, R.N., Fox, I., Perry, L, Wetzig, R., Takaoki, M., Nisonoff, A., Benacerraf, B., Sy, M.S. The role of idiotype in guiding cellular responses. In: Janeway, C., Sercarz, E., Wigzell, H. eds. ICN-UCLA Symposia, Immunoglobulin Idiotypes and Their Expression. 1981:725-729.

12. Germain, R.N., Sy, M.S., Rock, K., Dietz, M.H., Greene, M.I., Nisonoff, A., Weinberger, J.Z., Ju, S.T., Dorf, M.E., Benacerraf, B. The role of idiotype and the MHC in suppressor T cell pathways. In: Janeway, C., Sercarz, E., Wigzell, H., eds. ICN-UCLA Symposia, Immunoglobulin Idiotypes and Their Expression. Academic Press, 1981:709-723.

13. Abbas, A.K., Greene, M.I. Preferential regulation of idiotype secretion by anti-idiotypic supppressor T cells. In: Janeway, C., Sercarz, E., Wigzell, H., eds. ICN-UCLA Symposia, Immunoglobulin Idiotypes and their Expression. Academic Press, 1981.

14. Drebin, J.A., Perry, L.L., Bromberg, J., Nepom, J., Benacerraf, B., and Greene, M.I. The effects of antisera directed at I-region gene products on syngeneic tumor immunity. In: Nydegger, U.E., ed. Immunochemotherapy. Academic Press, 1981:99-108.

15. Bromberg, J.S., Takaoki, M., Sy, M.S., Tominaga, A., Perry, L.L., and Greene, M.I. The regulation of the immune response cell surface antigen. In: Fefer, A., and Goldstein, A.L., eds. The potential role of T cell subpopulations in cancer therapy. Progress in cancer research and therapy. Raven Press, 1981.

16. Schatten, S., Drebin, J.A., Takaoki, M., Carter, R., Tominaga, A., Abbas, A.K., Finberg, R., and Greene, M.I. Regulation of the immune response to cell surface antigens in B and T cell tumors. In: Vitetta, E., ed. ICN-UCLA Symposia. Academic Press, 1982.

17. Drebin, J.A., Shilo, B.Z., Weinberg, R.A., and Greene, M.I. Preliminary evidence of an association between an activated cellular transforming gene and a tumor specific transplantation antigen. In: Vitetta, E., ed., ICN-UCLA Symposia. Academic Press, 1982.

18. Zalutsky, M., Perry, L.L., Schatten, S., Kaplan, W., Greene, M.I. and Benacerraf, B. Imaging of human prostrate tumors in nude mice using radioiodinated monoclonal antibodies. In World Federation of Nuclear Medicine and Biology, 1982.

19. Drebin, J.A., Schatten, S., Tominaga, A., Lefort, S., Letvin, N.L., Bast, R., Mizel, S. and Greene, M.I. Characterization of ultraviolet radiation-induced impairment of antigen presenting cell function at the cellular and molecular level. In: Parrish, J., ed. The Effect of Ultraviolet Radiation on The Immune System. Johnson & Johnson, 1983.

20. Lowy, A., Tominaga, A., Drebin, J.A., Benacerraf, B., and Greene, M.I. Activation of suppressor cells is genetically restricted by the I-J subregion. Survey of Immunologic Research, 1983; 2:233-236.

21. Greene, M.I., Schatten, S., and Bromberg, J.S. Delayed hypersensitivity. In: Paul, W.E., ed. Fundamental Immunology. Raven Press, 1984.

22. Noseworthy, J.H., and Greene, M.I. Studies on idiotypes shared by neuronal and lymphoid cells. In: Cazanave, P.A. and Urbain, J.A. eds., Idiotype in Biology and Medicine. Academic Press, 1984; 15:303-328.

23. Schatten, S., Granstein, R.D., Drebin, J.A., and Greene, M.I. Suppressor T cells and the immune response to tumors. In: CRC reviews, 1984; 4:335-379.

24. Greene, M.I., Weiner, H.L., Dichter, M., and Fields, B.N. Syngeneic monoclonal anti-idiotypic antibodies identify reovirus type 3 hemagglutinin receptors on immune and neuronal cells. In: Venter, J.C., ed., Receptor Biochemistry and Methodology. S. Liss Publ. New York.

25. Granstein, R.D., Tominaga, A., and Greene, M.I. Therapeutic use of interleukins: experimental results. In Survey of Immunologic Research, 1984.

26. Greene, M.I., and Nisonoff, A., eds. The Biology of Idiotype. Plenum Press, 1984.

27. Drebin, J.A., Schatten, S., and Greene, M.I. The Role of Antigen-Presenting Cells in Regulating the Immune Response to Tumor Antigens. Transplanation Proceedings, 1984;5:1377-1379.

28. Fields, B.N., Sharpe, A.H., Spriggs, D.R., and Greene, M.I. The reovirus hemagglutinin: specific attenuation and antigenic mimicry as approaches for immunization. Cold Spring Harbor Symposia. 1984.

29. Granstein, R.D., Tominaga, A., Mizel, S.B., and Greene, M.I. Defective antigen presenting cell function and Interleukins. In Lymphokines, ed. S. Mizel, 1985:57-74.

30. Co, M.S., Gaulton, G.N., Matsuzaki, N., and Greene, M.I. Virus Receptors on Somatic and Immune Cells. Hybridoma Technology in the Biosciences and Medicine. Ed. Springer, T.A. Plenum Publ. Corp, 1985:341-351.

31. Carroll, A.M., Perry, L.L., Lowy, A. and Greene, M.I. Anti-IA antibodies in the Treatment of Autoimmune Disease: Regulation of Immune Response by In Vivo Admininistration of Monoclonal Anti I-A Antibodies. Ed. J. Clot and J. Sany, Academic Press Inc., 1986; 6:59-72.

32 Monroe, John G. and Greene, M.I. Anti-idiotypic Antibodies and Disease. Immunological Investigations. 1986; 15:263-286.

33. Greene, M.I. and Hamaoka, T. eds. Induction and Recognition of the Transformed Cell. Plenum Press, 1987.

34. Greene, M.I. and Fields, B.N. Host Response to Viruses Immunological Diseases Ed M. Frank. 1988; 899-921.

35. Maguire, H.C., Sibinga, E., Weiner, D.B., and Greene, M.I. The neu oncgene in human neuroblastoma cell lines. Advances in Neuroblastoma Research, Alan R. Liss, Inc. 1988; 2:165-173

36. Gaulton, G.N. and Greene, M.I. Regulation of Cell Growth and Immunity by Reovirus Anti-Receptor Antibodies. Anti-Idiotypes, Receptors and Molecular Mimicry. D.S. Linthicum, N.R. Farid, 1988; 301-309.

37. Williams, W.V., Weiner, D.B., Rubin, D.H., Guy, H.R. and Greene, M.I. Determination of the Neutralizing/Cell-Attachment Epitope of Reovirus Type 3. Technol. Advances in Vaccine Development, 1988; 577-586.

38. Greene, M.I. Vaccine Development. Therapeutic Advances in Clin. Immunology, 8:169-178, 1988.

39. Gaulton, G.N., Co, M.S., and Greene, M.I. Use of monoclonal anti-idiotypic antibodies as specific vaccines and as probes of the mammalian reovirus type 3 receptor. In: Monoclonal Antibodies and Cancer Therapy. ed. R. Reisfeld, Sell, S., Liss Publ., New York.

40. Co, M.S., Fields, B.N., and Greene, M.I. Viral Receptors that serve Host Functions in Contemporary Topics in Microbiology. eds. Oldstone, M. and Notkins, A.L, (in press).

41. Carroll, A.M., and Greene, M.I. Tumor Cell Biology: Tumor Specific and Associated Antigens. CRC Reviews ipp:14-43,1989.

42. Williams, W.V., Weiner, D.B. and Greene, M.I. Development and Use of Anti-Receptor Antibodies to Study Interaction of Mammalian Reovirus Type 3 with its Cell Surface Receptor. Methods in Enzymology, 1989;178:321-341.

43. Cohen, J.A., Williams, W. V., Weiner, D. B., Greene, M. I. Molecular Aspects of Ligand Interaction with Somatic and Immune Receptors: Insights from Studies of the Mammalian Reoviruses. Chemical Immunology, 1989; 46: 126-156.

43. Williams, W.V., Guy, R.H., Cohen, J.A., Weiner, D.B. and Greene, M.I. Structure and Regulation of Internal Image Idiotypes. Chemical Immunology, 1990; 48:185-208.

44. Weiner D.B.,Liu J.,Williams W.V., and Geene M.I., The role of cells and factors in immune suppresion in animal models: in The Role of Cells and Cytokines in Immunity and Infection J.J.Oppenheim and E.M.Shevach Eds. Oxford Press.

45. Kokai, Y., Wada, T., Myers, J., Brown, V., Dobashi, K., Cohen, J., Hamuro, J., Weiner, D., and Greene, M.I., The role of the neu Oncogene Product in Cell Transformation and Normal Development: in Immune System and Cancer T Hamaoka et al., Eds. Japan Society Press, 45-57, 1989.

46. Williams, W.V., Kieber-Emmons, T., Weiner, D.B., Greene, M.I. Use of antibodies as molecular mimics to probe intermolecular interaction landscapes. Molecular evolution on

rugged landscapes: Proteins RNA and the Immune System. A. Perelson and S. Kauffman, Eds., Addison Wesley Longman, 1991.

47. Kieber-Emmons, T., Williams, W.V., and Greene, M.I. Anti-receptor antibody structure and peptide design. Monoclonal Antibodies: Application and Clinical Oncology A. A. Epenetos, Chapman and Hall Medical, 1991.

48. Maier, C.C., Zhang, X., and Greene, M.I., The design of biologically active small molecular forms derived from functional anti-receptor antibodies. Handbook of Experimental Immunology, Fifth Edition. Blackwell Science, Cambridge, MA. 103, 1-8, 1996.

49. H.U. Saragovi, G.J. Sauvé, and M.I. Greene. 1992. "Viral receptors". In: Encyclopedia of Virology. Robert G. Webster and Allan Granoff, Eds. Saunders Scientific Publications, London.

50. Zerva, L., Cotsarelis, G., and Greene, M.I., From monoclonal antibodies to small peptides and mimetics: size and reduction of the binding site in the immunoglobulin superfamily. The Immunoglobulins, 1997.

51. Qian, X., and Greene, M.I., Her2/neu, A Receptor Tyrosine Kinase with Developmental and Oncogenic Activity., Encyclopedia of Cancer, Academic Press, Vol. 2, 835-856, 1997.

52. Brennan, P. and Greene, M.I., Her2/neu, Encyclopedia of Cancer, 2: 387-405, 2002.

Reviews:

1. Greene, M.I., Leszcz, M., Stefanson, D., and Wall R. Community Outreach. A new approach to the medical and social problems of the elderly. Canadian Council on Social Development, Canadian Welfare. 1975; 51:5-11.

2. Gurwith, M., Bourque, C., Cameron, E., Forrest, G., and Greene, M.I. Cholera-like diarrhea in Canada. Report of a case associated with Enterotoxigenic Escherichia coli and a toxin producing Aeromonas hydrophila. Arch Inter. Med. 1977; 137:1461-1464.

3. Greene, M.I., Pierres, A., and Benacerraf, B. The specific suppression of contact sensitivity. Arthritis Rheum. 1978; 21.5:100-104.

4. Greene, M.I., and Bach, B.A. Hypothesis: The physiological regulation of immunity: Differential regulatory contributions of peripheral and central lymphon compartments. Cell Immunol. 1979; 45:446-451.

5. Greene, M.I., and Perry, L.L. The relationship of alloreactivity to syngeneic tumor immunity. Transplant Proc. 1980; XII:80-85.

6. Nisonoff, A., and Greene, M.I. Regulation through idiotypic determinants of the immune response to P-azophenylarsonate hapten in strain A mice. Proc. 4th Intl. Congress, Fougereau, M., Dausset, J., Eds., Academic Press, 57-80.

7. Greene, M.I., Perry, L.L., Sy, M.S. and Bromberg, J. The I-J subregion and surveillance. Immunol. Today 1981, II:23-25.

8. Greene, M.I. Ligand-receptor-anti-receptor interaction in immunity. Immunol. Abs., 1981:495-500.

9. Benacerraf, B., and Greene, M.I. The thymus and immunity. In the Schiapparelli lectures on Immunogenetics and Immune Regulation. Benacerraf, B., ed. 1982: Masson Publishing, 1-29.

10. Drebin, J.A., Carter, R., Perry, L.L., and Greene, M.I. Regulation of the immune response to antigens on the malignant cell surface. Springer Seminars in Immunopathol., 1982:5:175-192.

11. Bromberg, J.S., Carpenter, C.B., and Greene, M.I. The genetics and mode of presentation of antigen determinants: Influence on immunologic responsiveness in transplantation. Human Immunol., 1982:4:157-166.

12. Nepom, J.T., Noseworthy, J.H., Tardieu, M., Epstein, R.,Weiner, H.L., Gentisch, J., Fields, B.N., and Greene, M.I. Virus binding receptors similarities to immune receptors as determined by anti-idiotypic antibodies. Survey of Immunologic Research, 1982:1:255-261.

13. Benacerraf, B., Greene, M.I., Sy, M.S., and Dorf, M.E. Suppressor T cell circuits. Annals of the New York Academy of Sciences, 1982:392:300-308.

14. Tominaga, A., Bromberg, J.S., Takaoki, M., Lefort, S., Noseworthy, J., Benacerraf, B. and Greene, M.I. Activational signals for immune effector and suppressor T cells reactive with haptenic determinants. Annals of the New York Academy of Sciences 1982; 392:309-317.

15. Borel, Y., and Greene, M.I. Cellular Immunity and tolerance to nucleic acids. Annals of the New York Academy of Science. 1982; 392:167-177.

16. Bromberg, J.S., Tominaga, A., Takaoki, M., and Greene, M.I. The I-J subregion and suppressor signals. Survey of Immunologic Research. 1982; 1:67-75.

17. Greene, M.I. Selected aspects of T cell function. Survey Immunol. Research. 1982;I:242-243.

18. Lowy, A., Tominaga, A., and Greene, M.I. I-J determinants as restriction and activation signals. Survey Immunol. Res. 1983; 2,3:233-236.

19. Tominaga, A., Lefort, S., Mizel, S., and Greene, M.I. Therapeutic effects of interleukin on radiation treated antigen-presenting cells in vivo and in vitro. Survey of Immunol. Research. 1983; 2,3:213-215.

20 Carroll, A.M., Zalutsky, M.R., Benacerraf, B., and Greene, M.I. Monoclonal Antibodies to Tissue-Associated Antigens as Antitumor Reagents. Surv. Synth. Path. Res. 1984; 3:189-200.

21. Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A. and Greene, M.I. Immune Responses Against Transforming Gene Associated Antigens. In: Regulation of the Immune System (E. Sercarz, H. Cantor, and L. Chess, ed.) Alan R. Liss, Inc. 1984;919-928.

22. Stern, D., Schechter, A., Vaidyanathan, L., Weinberg, R., Greene, M., and Drebin, J. The neu oncogene encodes a cell surface protein with properties fo a growth factor receptor. In: Genetics, Cell Differentiation, and Cancer (P.A. Marks, ed.). Academic Press 165-170. Academic Press 1985; 165-170.

23. Carroll, A.M., Perry, L.L., Lowy, A. and Greene, M.I. Regulation of Immune Response by In Vivo Administration of Monoclonal Anti I-A antibodies. Academic Press 1986; 59-72.

24. Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A., and Greene, M.I. Development of Monoclonal Antibodies Reactive with the Product of the Neu Oncogene. In: Immunology and Cancer (M. Kripke, editor). University of Texas Press. 1986;277-289.

25. Drebin, J.A., Link, V.C., and Greene, M.I. Monoclonal Antibodies Reactive with the Neu Oncogene Product Inhibit the Neoplastic Properties of Neu-Transformed Cells. In: Development and Recognition of the Transformed Cell (M.I. Greene and T. Hamaoka, ed.) Plenum Press. 1987;69-80.

26. Greene, M.I. and Co, M. Shared Structural Features of an Internal Image Bearing Monoclonal Anti-idiotype and the External Antigen. Monograph Allergy. 1987; 22:120-125.

27. Powell, M.B., and Greene, M.I. In vivo and in vitro delayed hypersensitivity. Methods in Enzymology.163:357-369, 1988.

28. Williams, W., H.R., Guy, Weiner, D., Rubin, D., and Greene, M.I. Structure of the neutralizing epitope of the reovirus type 3 hemagglutinin. Vaccines 88 25-28 1988

29. Cohen, J.A., Williams, W.V. and Greene, M.I.. Molecular aspects of reovirus - host cell interaction. Microbiological Sciences. 5:265-270, 1988.

30. Fox, I.J., Perry, L.L., Greene, M.I. The role of anti-I-A Antibody Therapy in the Management of Autoimmune Disease and in Transplantation. Advanced Drug Delivery Reviews, 1988;2:359-367.

31. Weiner D.B.,Siegel R.M. Williams W.V.,and Greene M.I. Lymphocyte Suppressive Network and soluble effector Mechanisms, 1988, Clinical Immunology Newsletter 9:184-188

32. Cohen, J.A., Sergott, R.C., Geller, H.M., Brown, M.J. and Greene, M.I. Mammalian Reovirus Receptor Expression by Oligodendrocytes. Annals of the New York Acad. Sci., 1988; 540:445-449.

33. Williams, W.V., Weiner, D.B., Rubin, D.H., and Greene, M.I. Antigenic structure of the neutralizing epitope of reovirus type 3. Immunology and Allergy Clincs of North America 8:159-172,1988

34. Williams, W.V., Moss, D.A., Weiner, D.B. and Cohen, J.A., Guy, H.R. and Greene, M.I. Antiidiotypic Modeled Peptides with Biologic Activity. Advances in Immunopharmacology. Ed. J.W. Hadden, F. Spreatico, Y. Yamamura, K.F. Austen, P. Dukor and K. Masek. Pergamon Press. 1989.

35. Williams W.V., Weiner D.B., Guy, H.R. and Greene M.I., Three dimensional structure of a functional internal image Viral Immunology 2:239-246, 1989.

36. Williams, W.V., Weiner, D.B., Cohen, J.C., and Greene, M.I. Development and use of receptor binding peptides derived from antireceptor antibodies Biotechnology 7: 471-475, 1989.

37. Williams, W.V., Weiner, D.B., Rubin, D.H., Greene, M.I.: Shared Antigenic Structure Defines of the Neutralizing Epitope of the Reovirus Type 3+ Therapeutic Advances in Clinical Immunology: Immunology and Allergy Clinics of North America 8: 169-172, 1989

38. Weiner, D.B., McCallus, D.E., Williams, W.V., Greene, M.I., Three dimensional structure of a functional internal image. Viral Immunology 2: 239-246, 1989

39. Weiner, D.B., Williams, W.V., Hoxie, J.A., Berzofsky, J.A. and Greene, M.I. Non-CD4 Molecules on Human Cells Important in HIV-1 Cell Entry. Vaccines, Cold Spring Harbor Press, 1989; 115-120.

40. Wadsworth, S., Yui, K., Yellen, A., and Greene, M.I. Thy-1, CD4 and CD8 in T Cell Development, Year in Immunol 4, 59-73, 1989.

41. Maguire, H.C., Jaworsky, C., Cohen, J.A., Hellman, M., Weiner, D.B., and Greene, M.I. Distribution of neu (c-erbB-2) Protein in Human Skin. Journal of Investigative Dermatology, 786-790, 1989.

42. Weiner, D.B., Hubner, K., Williams, W.V. and Greene, M.I. Species Tropism of HIV-1: Infectivity of Interspecific Cell Hybridomas Implies Non-CD4 Structures are Required for Cell Entry. Cancer Detection and Prevention 14,317-320,1990

43. Kelsten, M.L., Berger, M.S., Maguire, H.C., Chianese, D.A., Hellman, M.A., Weiner, D.B. and Greene, M.I. The Analysis of *c-erb*B2 Protein Expression in Conjunction with DNA Content Using Multiparameter Flow Cytometry. Cytometry 1:522-532,(1990).

44. Weiner D.B, Williams W.V., Merva M.J.,Berzofsky J.A., and Greene M.I., HIV infectivity: Analysis of virus envelope determinants and target cell requirements for infectivity by HIV-1 Vaccines 90,339-345, 1990.

45. Weiner D.B.,Huebner K.,Jameson B.,Williams W.V. and Greene M.I. Species tropism of HIV-1 infectivity of interspecific cell hybridomas implies non-CD4 structures are required for cell entry. Cancer Detection and Prevention 1990, 143: 317-319.

46. Lodato R.F.,Maguire H.C., Greene M.I., Weiner D.B., and LiVolsi V.A. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Modern Pathology 3,449-454,1990.

47. Maguire, H.C. Jr. and Greene, M.I.: Neu (c-erbB-2), a tumor marker in carcinoma of the female breast. Pathobiology, 58:297-303, 1990.

48. Williams, W.V., Weiner, D.B., Kieber-Emmons, T., and Greene, M.I. Antibody Geometry and Form: Three Dimensional Relationships Between Anti-idiotypic Antibodies and External Antigens. Trends in Biotechnology 8,256-263,1990

49. Williams, W.V., Kieber-Emmons, T., Weiner, D.B., and Greene, M.I. Molecular analysis of a ligand-receptor interaction using idiotype structure. Idiotype Networks in Biology and Medicine 243-249, 1990.

50. Williams, W.V., Weiner, D.B., Greene, M.I.: Molecular Analysis of Primary T Cell Involvement in the Idiotyp[ic Network Utilizing Immunoglobulin-Derived Peptides. The Year in Immunology 6: 152-161, 1990.

51. Sugimoto, M., Sharpe, A., Sato, Y., Greene, M.I., Fields, B.N. Reovirus transport-Studies using lymphocytosis promoting factor. Pathobiology 58: 185-192, 1990.

52. Myers, J.N., Drebin, J.A., Wada, T. and Greene, M.I.: Biological effects of monoclonal antireceptor antibodies reactive with the *neu* oncogene product, $p185^{neu}$. Methods in Enzymology, 198: 277-290, 1991.

53. Komori, S., Siegel, R.M., Yui, K., Katsumata, M., and Greene, M.I., "T-Cell Receptor and Autoimmune Disease", Immunol. Res., 9: 245-264, 1990.

54. Cohen, J.A., Williams, W.V., More, K.F., Sehdev, H., Davies, J.G., Greene, M.I. Ligand binding to the cell-surface receptor for reovirus type 3 alters Schwann cell growth and function. Annals of the New York Academy of Science 1991

55. Williams, T. M., Weiner, D.B., Greene, M.I., Maguire, H.C. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 59: 46-52, 1991

56. Weiner, D.B., McCallus, D.E., Williams, W.V., Greene, M.I. Utilization of anti-idiotypic antibodies as molecular probes of virus-receptor interactions. Progress in Vaccinology Anti-Idiotypic Vaccines pp92-106,1991.

57. Brown, V.I. and Greene, M.I., Molecular and Cellular Mechanismds of Receptor-Mediated Endocytosis. DNA and Cell Biology, 10: 399-409, 1991.

58. Bhandoola, A., Yui, K., Siegel, R.M., Zerva, L., and Greene, M.I.,"GLD And LPR Mice: Single Gene Mutant Models For Failed Self Tolerance", Intern. Rev. Immunol., 11: 231-244, 1994

59. Markmann, J.F., Bhandoola, A., Seidman, C., Campos, L., Greene, M.I., and Barker, C.F., Rejection of MHC Defecient Grafts by Indirect Antigen Presentation., Surgical Forum, 45,417-418,1994.

60. Dougall, W.C. and Greene, M.I., Biological Studies and Potential Therapeutic Applications of Monoclonal Antibodies and Small Molecules Reactive with the neu/cerbB-2 Protein, Cell Biophysics, Humana Press Inc., 24/25:209-218, 1994.

61. Yui, K., Bhandoola, A., Tamura, A., Son, C.B., Katsumata, M., Komori, S., Kajino, K., Kajino, Y., Zhang, X., Bromberg, J.S., Maier, C.C., and Greene, M.I., T cell tolerance and its relationship to autoimmunity in T cell receptor transgenic mice., Transgenics, 2: 1-21, 1996.

62. Kieber-Emmons T,, Murali R., and Greene M.I. Therapeutic Peptides and Peptidomimetics. Current Topics in Biotechnology,8:435-441,1997.

63. O'Rourke, D.M., Zhang, X., and Greene, M.I., Principles of receptor-based inhibition of erbB family receptor kinases: prospects for new therapies for human cancers. Proceedings of the Association of American Physicians, 109(3) 209-219, 1997.

64. Murali, R. and Greene, M.I. Structure-based design of immunologically active therapeutic peptides. Immunol. Res., 17: 163-169, 1998.

65. Zhang, H., Zhang, Q., Greene, M.I., and Murali, R., New Perspectives on Anti-HER2/Neu Therapeutics. Drug News & Perspectives, 13 (6) 325-329, 2000.

66. Brennan, P.J. and Greene, M.I. Neu Oncogene. Encyclopedia of Genetics, 2001.

67. Brennan, P.J. and Greene, M.I. Orphan Receptor. Encyclopedia of Genetics, 2001.

68. Berezov, A., Zhang, H.T., Greene, M.I., and Murali, R. Biacore Analysis of Rationally Designed anti-HER2 Exocyclic Mimetics of Antibodies, Biacore AB, 8: 4-7, 2001.

69. Hasegawa, A., Takasaki, W. Greene, M. I., and Murali, R. Modifying TNFα for Therapeutic Use: A Perspective on the TNF Receptor System, Mini Reviews in Medicinal Chemmistry, 1:5-16, 2001.

70. Brennan, P.J., Kumagai, t., Berezov, A., Murali, R. and Greene, M.I. HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene, 21(2): 328, 2002.

71. Li, B., Zhao, H., Liu, Q., Murali, R., Greene, M.I., and Zhang, H. Deoxycholate-based Method to screen phage display clones for uninterrupted open reading frames. Biotechniques, 33(2): 294-6, 2002.

Letters:

1. Greene, M.I., Peer Review: "The peer-review system would be improved dramatically if reviewers signed their names to the manuscripts they review." J. of NIH Research 2: 18-20, 1990.

EXHIBIT E

PATENTS

1. Cohen, J.A., Greene, M.I., Williams, W.V.: Method of stimulating myelination of cells. U.S. Patent Number 5,219,837; 1993.

2. Greene, M. I., Saragovi, H. U., Kahn, M.: Compositions which are immunologically crossreactive with antibodies and preparative methods therefor. U.S. Patent Number 5,334,702; 1994.

3. Weiner, D.B., Greene, M.I., Williams, W.V.: Peptides derived from human immunodeficiency virus-1 GP160. U.S. Patent Number 5,338,829; 1994.

4. Greene, M.I., Dobashi, K., Davis, J.G., Hamuro, J.: Ligand for the neu gene product. U.S. Patent Number 5,464,751; 1995.

5. Cohen, J.A., Greene, M.I., Williams, W.V.: Method of stimulating myelination of cells. U.S. Patent Number 5,574,009; 1996.

6. Greene, M.I., Williams, W.V., Weiner, D.B., Cohen, J.A., Kieber-Emmons, T., Williams, R.M.: Biologically active compounds and methods of constructing and using the same. U.S. Patent Number 5,637,677; 1997.

7. Greene, M.I., Zhang, X.: Compounds that bind to p185 and methods of using the same. U.S. Patent Number 5,663,144; 1997.

8. Greene, M.I., Davis, J.G.: Saccular collagen and compositions and methods for making and using the same. U.S. Patent Number 5,702,948; 1997.

9. Greene, M.I.: Methods of treating cancerous cells with anti-receptor antibodies. U.S. Patent Number 5,705,157; 1998.

10. Greene, M.I., Cotsarelis, G.: Methods of enhancing epithelial cell proliferation. U.S. Patent Number 5,753,226; 1998.

11. Greene, M.I., Drebin, J.A.: Treatment of tumors with monoclonal antibodies against oncogene antigens. U.S. Patent Number 5,824,311; 1998.

12. Greene, M.I., Qian, X.: Compositions and methods of treating tumors. U.S. Patent Number 5,837,523; 1998.

13. Greene, M.I., Davis, J.G.: Saccular collagen and compositions and methods for making and using the same. U.S. Patent Number 5,891,850: 1999.

14. Greene, M.I., Zhang, X.: Compounds that bind to p185 and methods of using the same. U.S. Patent Number 5,919,764; 1999.

15. Greene, M.I.: Constrained peptides. U.S. Patent Number 6,100,377; 2000.

16. Greene, M.I., Murali, R., Takasaki, W.: Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses. U.S. Patent Number 6,265,535; 2001.

17. Greene, M.I., Williams, W.V., Weiner, D.B., Cohen, J.A., Kieber-Emmons, T., Williams, R.M.: Biologically active compounds and methods of constructing and using the same. U.S. Patent Number 6,372,884; 2002.

18. Greene, M.I., O'Rourke, D.M., Murali, R., Park, B-W.: Compositions and methods of treating tumors. U.S.Patent Number 6,417,168; 2002.

19. Greene, M.I., Murali, R., Kinosaki, M. Methods of inhibiting osteoclast activity. U.S. Patent Number 6,673,771; 2004.

20. Greene, M.I., Murali, R., Aoki, K., Horne, W.C., Baron, R. Methods of inhibiting osteoclastogenesis. U.S. Patent Number 6,682,739; 2004.

21. Greene, M.I., Katsumata, M. Prevention of tumors with monoclonal antibodies against neu. U.S. Patent Number 6,733,752; 2004.

22. Greene, M.I., Eberwine, J., Kacharmina, J. E., Zhang, H.T. Methods, systems and kits for immuno-detection of epitopes expressed on molecules. U.S. Patent Number 6,743,592; 2004.